# "FAST-ABSORBING POLYGLACTIN 910 VERSUS CHROMIC CATGUT ISUTURE FOR REPAIR OF EPISIOTOMY: A RANDOMIZED COMPARATIVE STUDY"

#### By

Dr. Jada Susmitha



Dissertation submitted to BLDE (Deemed to be University), Vijayapura. In partial fulfilment of the requirements for the award of the degree of

#### MASTER OF SURGERY

IN

#### **OBSTETRICS AND GYNAECOLOGY**

Under the guidance of

#### Dr. Shailaja R Bidari

Professor Department of OBSTETRICS AND GYNAECOLOGY

# BLDE (DEEMED TO BE UNIVERSITY) SHRI B.M. PATIL MEDICAL COLLEGE, HOSPITAL & RESEARCH CENTRE, VIJAYAPURA, KARNATAKA.

2019

#### "FAST-ABSORBING POLYGLACTIN 910 VERSUS CHROMIC CATGUT SUTURE FOR REPAIR OF EPISIOTOMY: A RANDOMIZED COMPARATIVE STUDY "

#### **B.L.D.E (DEEMED TO BE UNIVERSITY)**

#### VIJAYAPURA



## MASTER OF SURGERY IN OBSTETRICS AND GYNAECOLOGY

## **ABBREVATIONS**

- ACOG American College of Obstetricians and Gynaecologist
- CC Chromic catgut
- EA European Pharmacopoeia
- EAS External Anal Sphincter
- FAP Fast absorbing polyglactin 910
- IAS Internal Anal Sphincter
- RCOG -Royal College of Obstetricians and Gynaecologists
- USP United States Pharmacopoeia
- BMI Body mass index
- BP-Blood pressure
- CVS Cardiovascular system
- EDD- Expected date of delivery
- EFW Estimated fetal weight
- IP NO. Inpatient number
- LMP Last menstrual period
- **RS-** Respiratory System
- USG-Ultrasound
- SD Standard deviation

# BACKGROUND

Episiotomy is a surgical incision made in the perineum during the second stage of labour to extend the vaginal introitus and ease delivery. During delivery eighty five percent women who give birth will have to some extent perineal trauma ,and almost 2/3 <sup>rd</sup> of them need perineal tear repair. Of these mothers many experience perineal pain not just in immediate postpartum period but also at a later period postnatally.<sup>8</sup>

The repair of episiotomy by different types of suture material which is being used will have impact over the amount of pain and superficial dyspareunia in women over time both in the immediate postpartum period and also later as well.<sup>9</sup>

During delivery it is of utmost importance to take adequate care so as to reduce risk of damage to perineum at birth so as to prevent discomfort from perineal sutures.<sup>10</sup>

Hence appropriate suture material with best properties are chosen for perineal repair. As standard suture material for many years chromic catgut is being used for perineal repair.<sup>11</sup>

Newer suture materials like Polyglactin 910 are being used which raises question as to shift towards this as standard suture material. These days various other suture materials are available for repair of perineal lacerations caused by child-birth. Absorbable suture materials like Polyglactin 910 is less painful and causes better healing than chromic catgut. The need for removal of it due to its persistence is its commonest disadvantage.<sup>10,12</sup>

Compared to the standard polyglactin 910 suture material ,the fast absorbing variety is pre-treated to accelerate hydrolysis which gets absorbed in 42 days unlike standard polyglactin 910 which is 63 days and 90 days in case of chromic catgut. <sup>11</sup>

The advantage of synthetic material fast absorbing polyglactin 910 is the absence of problems associated with delayed reabsorption of suture material.<sup>12</sup>

These synthetic materials like polyglactin 910 and polyglactin rapide 910 are associated with less pain in sitting postures and while walking and also the need for analgesics is decreased as compared to chromic catgut. <sup>13</sup>

Hence, a study was conducted to compare the Synthetic polyglactin rapide 910 2-0 vs chromic catgut in our institution.

## **OBJECTIVES OF STUDY**

To compare and evaluate the healing characteristics of fast- absorbing polyglactin 910 versus chromic catgut suture for episiotomy repair in terms of

- 1. Postpartum perineal pain and need for analgesia
- 2. Nature of wound healing

## **METHODS**

A total of 200 women were taken into study and were allocated randomly into group A belonging to chromic catgut No 1 and group B fast absorbing polyglactin 910 no 2-0 for repair of episiotomy. After a thorough examination, the results were evaluated at 24-48 hours , 10-14 days and 6-8 weeks postnatally.

## **RESULTS**

All the women included in the study were followed up at regular intervals and completed follow up successfully with no drop outs. Both the groups were compared with respect to demographical details such as age, period of gestation, Body mass index, Parity index.

In this study, the early postpartum period included 24 to 48 hours, during which there was a statistically significant difference (P=0.0031) in terms of perineal discomfort, with 18% of Group 1 experiencing severe pain and just 6% of Group 2 experiencing the same.

In addition, 54 percent of individuals in Group 1 reported tightness/uncomfort at the suture site, but 83 percent in Group 2 had no such complaints, which was statistically significant (P0.0001). After 10 - 14 days of postpartum we found that 61% of women were pain free in Group 2 as compared to 26% of Group 1 subjects and it was statistically highly significant(P<0.0001).

The trend of decreasing perineal pain was evidently demonstrated at 6 weeks postpartum, in the fast absorbing polyglactin 910 group (P=0.0235). Which was yet again proved as the need for analgesia was more in Group 1 as compared to Group 2 (P=0.0434).

We also discovered that the number of individuals with wound gaping in Group 1 was 14 percent, compared to just 4 percent in Group 1 after 10 to 14 days, which was statistically very significant (P=0.0135). None, however, required resuturing.

At 6 weeks postpartum, women in Group 1 revealed residual sutures in comparison to women in Group 2 (0 percent vs 13 percent, p value = 0.002). In terms of wound healing in both groups when compared at 6 weeks postpartum there was no statistically significant difference.

The wound infection rate as compared in both the groups was not statistically significant after 24 to 48hrs and 10 to 14 days postpartum, but after 6 weeks 4% of subjects in Group 1 had infection while none had in Group 2 (P=0.0434) being statistically significant.

# **CONCLUSION**

This study shows that most of women who had episiotomy experience varying degrees of pain in postpartum, some of them continue to endure the same even at 6 weeks postpartum.

After 24-48 hrs following delivery in immediate postpartum period there was significant difference in the pain and discomfort perceived by the 2 groups which was seen at 10 - 14 days and also at 6weeks revealing distinct advantage of the fast absorbing polyglactin910 suture over the chromic catgut in terms of perineal pain and comfort.

Upon assessing wound healing at 24-48 hrs, at 10-14 days both the groups were found to be similar although the complications related like superficial wound

breakdown were established to be more in the chromic catgut group which was significant. At 6 weeks yet again no significant difference was seen in wound healing .

As a result, we discovered that the Fast-absorbing version of Polyglactin is effective in reducing some of the morbidity associated with perineal healing after delivery. There was significant decline with regards to pain perception and discomfort.

There was a considerable reduction in the need for analgesics.

The occurrence of wound dehiscence was significantly reduced, reducing the need for resuturing. None required suture removal as well.

As a result, rapid absorbing polyglactin 910 could be considered in place of conventional chromic catgut for perineal repairs.

# Key words

Fast absorbing polyglactin 910; chromic catgut; episiotomy wound repair

# CONTENTS

SL No.	CONTENT	PAGE No.
1.	INTRODUCTION	17
2.	AIMS AND OBJECTIVES	47
3.	METHODOLOGY	48
4.	REVIEW OF LITERATURE	50
5.	RESULTS	55
6.	DISCUSSION	79
7.	SUMMARY	83
8.	CONCLUSION	84
9.	BIBLIOGRAPHY	85
10.	ANNEXURES	91

#### LIST OF FIGURES

- Figure 1- Right medio lateral episiotomy
- Figure 2 Suturing of all three-layer episiotomy wound
- Figure 3 Chromic Catgut and Fast absorbing polyglactin 910
- Figure 4 The pudenda
- Figure 5 Anterior and Posterior Triangles
- Figure 6 Anal Sphincter
- Figure 7 Types of Episiotomy
- Figure 8 Infiltration with Local Anesthesia
- Figure 9 Performing Mediolateral Episiotomy
- Figure 10 Episiotomy Scissors
- Figure 11- Identification of anatomical landmarks before episiotomy repair
- Figure 12- Closure of mucosal layers starting from apex
- Figure 13 Closure of muscle layer
- Figure 14 Perineal tear
- Figure 15 Stages of wound healing
- Figure 16 Tensile strength of suture materials
- Figure 17 Absorption rates of absorbable sutures

#### **TABLES:**

- Table 1: Age distribution of study population
- Table 2: BMI distribution of study population
- Table 3: Gestational age distribution in study population
- Table 4: Distribution of gravidity status in study population
- Table 5: Distribution of parity status in study population
- Table 6: Distribution of living issues in study population
- Table 7: Distribution of deaths in previous pregnancies in study population
- Table 8: Distribution of abortions in previous pregnancies in study population

Table 9: Perineal tears encountered in study population

Table 10: Analgesics used in study population

Table 11: Perineal pain perception after 24 to 48 hours of delivery in the studypopulation

Table 12: Perineal pain perception after 24 to 48 hours after delivery accordingto VAS pain scale in the study population

Table 13: No of after 24 to 48 hrs after delivery dosages of analgesics in study population

Table 14: Comparison of the discomfort/tight sutures experienced by both groups at 24 - 48 hrs.

Table 15: comparison of the infection rate in both groups after 24 to 48 hours post-partum

Table 16: Perineal pain perception after 24 to 48 hours of delivery in the study population

Table 17: Perineal pain perception after 10 to 14 days after delivery according to VAS pain scale in the study population

Table 18: Comparison of the discomfort/tight sutures experienced by both groups at 10 -14 days

Table 19: Comparison of the infection rate in both groups after 10 - 14 days post-partum

Table 20: Comparison of the wound gaping in both groups after 10 - 14 days post-partum

Table 21: Comparison of the residual pain perception in both groups followed by6 weeks post-partum

Table 22: Comparison of the residual sutures in both groups followed by 6 weeks post-partum

Table 23: Comparison of infection rate in both groups after 6 weeks post-partumTable 24: Comparison of wound healing in both groups after 6 weeks post-

partum

Table 25: Comparison of wound healing in both groups after 6 weeks post-partu

## **INTRODUCTION**

Episiotomy is one of the most common procedures performed by an Obstetrician in the Labour Room. It is practised from 18th Century. An incision taken on the pudendum is called Episiotomy which is used in regular practise. The two principal categories are Midline and mediolateral episiotomies and alter by the level of perineal incision. When a fourchette midline episiotomy is performed, the perineal body in the midline is cut through before the external anal sphincter. Depending on the perineal length and degree of thinning the incision varies from 2 to 3 cm. At midline of the fourchette to the left or right at an angle 60 degrees the mediolateral episiotomy begins which is usually adapted method . <sup>(1)</sup> During crowning the angle accounts for distortion of perineal anatomy and leads to an incision of 45 degree from the midline for suturing . <sup>(2)</sup>

From the midline the lateral episiotomy begins 1 to 2 cm lateral to it angled either right or left from ischial tuberosity. As the crowning occurs a mediolateral episiotomy is given. <sup>(3)</sup> Analgesia is given prior to episiotomy with 2.5 % lidocaine – prilocaine cream while some suggest usage of 1 % lidocaine .1% Lidocaine is used more widely as it takes 1 hour for its effect to occur which is logistically difficult to practise. <sup>(4)</sup>

Episiotomy timing is pivotal because if conducted too early, incisional haemorrhage can arise, and if performed too late, lacerations can develop. When the head is visible during contraction to a diameter of 4 cm or less, episiotomy is usually performed. During forceps delivery episiotomy is given almost as a rule before application of blades. By comparing midline and mediolateral episiotomy types ,midline episiotomy is associated with anal sphincter lacerations. <sup>(5)</sup>

Self-perceived pain and dyspareunia are more associated with mediolateral episiotomy. <sup>(6)</sup> There was little difference in pain scores, dyspareunia, and trauma to the vaginal or perineal injuries, including OASIS, in one of the trials that comprised lateral and mediolateral types in primigravida. They also

claimed that mediolateral episiotomies need less time and suture to heal than lateral episiotomies, thus mediolateral episiotomies are the favoured incision. <sup>(7)</sup>



Figure 1- Right medio lateral episiotomy

The kind of suture material used mostly for episiotomy repair after delivery can have an influence on the pain and superficial dyspareunia women endure in the short and medium haul.<sup>9</sup>

The goal of obstetric care is to limit the risk of perineal injury during birth and to minimise pain and discomfort from perineal sutures<sup>10</sup>.

As a result, it's important to identify sutures with the optimum characteristics for perineal healing.

Historically, these decisions have been influenced more by habit and expert advice. Chromic catgut has been the customary suture material for episiotomy healing for many years<sup>11</sup>.





 Closure of the vaginal mucosa by a continuous suture.

 The crown suture, reuniting the divided bulbocavernous muscle.



and fascia with interrupted sutures. Source: G. D. Posner, Jessica DY, A. Black, G. D. Jones: Human Labor & Birth, 6th Edition www.obgyn.mhmedical.com Copyright © McGraw-Hill Education. All rights reserved.

Figure 2 – Suturing of all three-layer episiotomy wound

With the development of newer absorbable suture materials, it's unclear if this criterion is still valid.

There are several different absorbable suture materials that may be used to mend perineal lacerations caused by childbirth. Synthetic absorbable sutures like Polyglactin 910 causes less pain and more secure healing than chromic catgut. Its disadvantage is persistence of the material that commonly needs removal.<sup>10,12</sup>

Standard polyglactin 910 suture material has been pre-treated with ionising rays to hasten hydrolysis in the rapid absorbing variant. This newer substance is referred to as fast absorbing. Polyglactin takes 42 days to absorb on average,

whereas Standard Polyglactin 910 takes 63 days and Chromic catgut takes about  $90 \text{ days}^{11}$ .



Figure 3 – Chromic Catgut and Fast absorbing polyglactin 910

Fast-absorbing polyglactin 910 sutures (Vicryl-rapide; Ethicon) may be able to provide the benefits of synthetic materials in the close future while avoiding the difficulties associated with delayed suture reabsorption<sup>12</sup>. Removal of residual suture material was more common in polyglactin 910<sup>13</sup>.

According to many trials and research, the recently developed fast absorbing polyglactin 910 possesses synthetic suture material characteristics as well as the benefit of rapid absorption. However, this is not a common practise. As a result, this study was undertaken to compare it to the traditional suture material utilised at our hospital for episiotomy incisions.

# **BACKGROUND**

# **RELEVANT ANATOMY**

# VULVA SANS PUDENDA

Pubis to perineum all the structures that are visible externally are included in the vulva namely -Mons pubis, Labia majora , Labia minora, Hymen ,Clitoris ,Urethral opening , Vestibule ,Various glandular structures.<sup>15</sup>



Figure 4 - The pudenda

# MONS PUBIS

It lies over symphysis pubis and is filled with fat and covered by curly hair after puberty and called as escutcheon<sup>15</sup>

# LABIA MAJORA

It is continuous with Mons Pubis directly and joins the perineum posteriorly and forms posterior commissure. It is covered with hair after puberty. It is richly supplied by sebaceous glands .The layer of dense connective tissue beneath skin is nearly devoid of muscular elements. It has rich venous plexus supply. In parous women the vasculature commonly develops varicosities during pregnancy.<sup>15</sup>

# LABIA MINORA

It is a fold of thin tissue of either side of labia majora medially.

Both the folds of tissues superiorly converge and are further bifurcate into two lamella. The lower pair merge into frenulum of the clitoris. The upper pair together form the prepuce .Inferiorly they form fourchette at midline .

It is structurally made of connective tissue along with some muscular fibres and many vessels. It is also supplied with various nerve endings which are very sensitive.

It is covered by stratified squamous epithelium. It has sebaceous glands , some sweat glands but no hair follicles.  $^{\rm 15}$ 

# CLITORIS

It consists of glans ,corpus and 2 crura. It is the female erogenous organ principally which is small around 2cm in length and less than 0.5cm in dimeter. It is supplied by rich nerve endings which are extremely sensitive and covered by stratified squamous epithelium.<sup>15</sup>

## VESTIBULE

It is an almond shaped structure that is covered by labia minora laterally. It extends from fourchette to clitoris posteriorly to anteriorly respectively. It is perforated by 6 openings namely the Urethra, Vagina ,ducts of Bartholin and paraurethral glands and also of skene glands.<sup>15</sup>

## VESTIBULAR GLANDS

They are situated underneath vestibule about 0.5 to 1cm diameter, each of which open on either side of opening of vagina. At the lateral margin of orifice of vagina just outside the ducts open which are of 1.5cm to 2cm in length. They release mucoid material during sexual arousal.<sup>15</sup>

## VESTIBULAR BULBS

On either side of vestibule beneath the mucous membrane erectile tissue aggregations which are almond shaped are present .They are richly supplied by veins and end at the middle of vaginal opening and extend towards clitoris upwards. These tissues can get injured during child birth and may rupture even and form vulval hematoma.  $^{15}$ 

## VAGINAL OPENING AND HYMEN

Often in virgins ,the vaginal opening is closely hidden by overlapping labia minora. The hymen differs greatly in shape and consistency and is majorly composed of elastic and collagenous connective tissue and is covered by stratified squamous epithelium. It is devoid of glandular and muscular elements and is minimally supplied with nerve fibres. Due to childbirth changes called hymen caruncles takes place where in, it is present in the form of cicatrized nodules.<sup>15</sup>

# PUDENDAL NERVE AND VESSELS

It is the motor and sensory nerve of perineum which runs parallel to the pudendal vessels. The pudendal vessels connect with internal iliac vessels.

The pudendal nerve originates from the sacral plexus (S2,S3,S4). The pudendal artery originates from anterior division of internal iliac artery. Both the nerve and vessels are divided into 3 branches

1. The clitoral branch

2. The perineal branch (largest branch of the three)

3. The inferior hemorrhoidal branch<sup>15</sup>

#### VAGINA

It is a structure which is Musculo-membranous in nature which extends from vulva to uterus. It is anteriorly and posteriorly interposed between bladder and rectum respectively.

The vagina is anteriorly separated by vesicovaginal septum from bladder and urethra.

It is separated at the level of lower portion of vagina from rectum posteriorly by rectovaginal septum. At the upper fourth of vagina it is separated by pouch of Douglas from the rectum.

The vaginal walls normally form H shape in cross-section by the anterior and posterior walls. The mucosa consists of non-cornified stratified squamous epithelium.

There are no glandular tissues .It is lubricated hence by the transudate which originates from subepithelial capillary plexus and from the cervical secretions.

Occasionally fragments of stratified epithelium get embedded in vaginal connective tissue after childbirth. They can form inclusion cysts in vagina which do not classify under true glands.<sup>15</sup>

# PERINEUM

It is the area which is diamond shaped present between the thighs. The pubic symphysis, ischiopubic rami, ischial tuberosities, posterolaterally sacrotuberous ligaments, and posteriorly the coccyx form the anterior boundary.

The perineum is divided into anterior and posterior triangle by an arbitrary line which joins the ischial tuberosities. <sup>15</sup>



Figure 5 - Anterior and Posterior Triangles

## ANTERIOR TRIANGLE (UROGENITAL TRIANGLE)

Pubic rami, ischial tuberosities, and superficial transverse perineal muscles form the superior and lateral borders, respectively. It is further separated into superficial and deep compartments by the perineal membrane.

The perineal membrane consists of dense fibrous tissue ,triangular in shape and covers anterior half of pelvic outlet. Previously it was thought to be of 2 layered

structure. It attaches medically to distal part of urethra and laterally to ischiopubic rami and towards posteriorly to the perineal body.<sup>15</sup>

# POSTERIOR TRIANGLE

It consists of ischiorectal fossa, anal canal and sphincter complex ,internal pudendal vessels branches and pudendal nerve. <sup>15</sup>

# ISCHIORECTAL FOSSA

It is found on either side of anal canal filled with fat ,wedge shaped and it is majorly constitutes the posterior triangle. It is medially bound by the levator ani and obturator internus muscle anterolaterally. They communicate behind the anal canal posteriorly. This fossa is important clinically as it can get involved with episiotomy infection.<sup>15</sup>

# ANAL SPHINCTERS

These are divided into external and internal sphincters which surround the anal canal and provide continence. They are prone for tears during vaginal delivery and are present proximal to vaginal .Majority of the tears remain unidentified during vaginal delivery.<sup>15</sup>



Figure 6 - Anal Sphincter

# EXTERNAL ANAL SPHINCTER (EAS)

This consists of straited muscle fibres in the form of rings which attaches anteriorly to perineal body and posteriorly to coccyx. At resting state they maintain a constant state of contraction leading to increased tone and strength and relax during defecation. It is further classified into superficial, deep and subcutaneous fat.

Around anal canal an encircling ring is formed by the subcutaneous portion attachment of the anal sphincter to the perianal skin. It leads to formation of radially oriented characteristic folds in perianal skin. The deeper fibres encircle rectum and with puborectalis they form a loop under the dorsal surface of anorectum.<sup>15</sup>

# INTERNAL ANAL SPINCTER (IAS)

These fibres are responsible for contributing to the resting pressure and prior to defecation relaxation occurs. The sphincter constitutes distal part of inner circular smooth muscle layer of colon and rectum. It is of 3 to 4 cms in length and 1 to 2 cms away from distal margin of external sphincter. In 4th degree perineal tears internal anal sphincter maybe involved. <sup>15</sup>

# PERINEAL BODY (CENTRAL TENDON OF THE PERINEUM)

It is present between anus and vagina formed by the median raphe of levator ani strengthened by mass of connective tissue. It is a converging point for muscles such as superficial transverse perini, bulbocavernosus and external anal sphincter. During episiotomy perineal body is incised.

Functions:

- 1. Anchoring vagina and the anorectum
- 2. Helps in maintenance of urinary and faecal continence
- 3. Orgasmic platform is maintained
- 4. Helps in prevention of urogenital hiatus expansion
- 5. It is a physical barrier between rectum and the vagina<sup>15</sup>

## EPISIOTOMY DEFINITION:

Episiotomy refers to a surgical planned incision intervention upon on the perineum and posterior vaginal wall as during second stage of giving birth (perineotomy)

## HISTORY:

The earliest evidence found in the literature so far documented was first proposed by Sir Fielding Ould in mid 18<sup>th</sup> century in Textbook of obstetrics, Ould described incision of perineum as a means of saving the child's life during difficult delivery.<sup>15</sup>

Although numerous physicians in Europe tried it in their own ways, it still remined obscure over the next hundred years.

Several modifications were suggested with regards to Oulds methods in the first half of 19<sup>th</sup> century.

The very first physician who reported performing perineal incision was from Hamburg, Germany namely G.Ph.Michaelis.<sup>16</sup>

Ritgen in 1820 suggested multiple superficial incisions around vaginal orifice for preventing perineum from rupture. He mentioned it in his textbook on Use of Mechanical Aids for Childbirth.

It was only in 1847 that the practise of mediolateral episiotomy that is practised today was first suggested by Prof Dubois in France.<sup>15,16</sup>

Eichelberg and Scanzoni suggested lateral and bilateral episiotomy in 1850 and 1852.

The word 'Episiotomy' was first coined by Carl Braun of Vienna in 1857 which translated to cutting of vulva or pubic area. Although Braun had condemned its usage and deemed it unnecessary.<sup>16</sup>

In USA it was performed for the first time by a Virginian surgeon in 1851.

During a period between 1870's and 1920's Episiotomy was accepted as a last resort operation and was condemned by a large number of obstetricians in USA, England ,Ireland and Scotland. It was advised only as an operation of desperation.

In the early 20<sup>th</sup> century with the control of sepsis and introduction of various anaesthetic methods Episiotomy was largely accepted into routine practise.

By 1930's majority of literature on Obstetrics advocated episiotomy as a prophylactic measure in events such as:

- (a) In preventing damage to pelvic floor and posterior vaginal wall
- (b) In safeguarding gross injury to anal canal wall and sphincter ani muscle
- (c) In preventing extensive laceration caused by overdistention of vaginal wall
- (d) To preserve sphincter integrity during difficult delivery by providing a clean cut wound
- (e) To facilitate safe and easy delivery of foetus by enlarging the passageway of the vaginal introitus

Many physicians and obstetricians debated over the alternative techniques regarding median and the mediolateral approach in using Episiotomy rather than its safety of usage primarily.<sup>15</sup>

After World War II, In USA routine episiotomy was increasingly advocated which resulted in 62.5% of vaginal deliveries by 1979.

In UK up-to 21% of vaginal deliveries had episiotomy in 1958 and 91% in 1978. As the naturalist movement moved on in 1970 routine practise of usage of episiotomy was questioned and slowly obstetricians started establishing restricted usage of episiotomy.

On evaluating 1576 spontaneous deliveries consequently in 2000 by Robinson and his associates came to a conclusion that midwives had lower incidence of usage of episiotomy (21%) when compared to medical schools (33%). The highest rates were among private practitioners (55%). <sup>(17)</sup>

The idea of practising Episiotomy routinely in vaginal delivery has been strongly challenged. Recent evidences state that there is no improved neonatal outcome nor there is reduction of perineal trauma of operative delivery as opposed to the previous school of thought of decreasing the risk of perineal injury.<sup>(18)</sup>

In 2014 Amorim found that non episiotomy and deliveries had episiotomy both had no significant difference with respect to duration of second stage of labour , perineal teras, need for perineal suturing and blood loss during delivery. <sup>(19)</sup>

Rochner and associates used vaginal cones to study pelvic floor muscle strength and found that women with history of episiotomy had less strength when compared to spontaneous delivery. Other studies showed upon neural testing of perineal muscles that the amount of denervation was related to the birthweight of the baby and the duration of second stage of labour which had no relation with episiotomy. <sup>(20)</sup>

Multiple studies and trails have found no good data to support the prophylactic use of episiotomy in all vaginal deliveries for prevention of perineal trauma as routine practise. Many experts opinionated that episiotomy is to be used in restrictive manner as it is quite helpful in difficult deliveries like shoulder dystocia.

The American College of Obstetrics and Gynaecologists <sup>(21)</sup> have concluded that episiotomy is to be used restrictively which is also supported by Royal college of obstetrics and gynaecology in their revised guidelines. <sup>(22)</sup>

#### **INDICATIONS:**

Breech delivery Shoulder dystocia Persistent OP positions Fetal macrosomia

Operative vaginal deliveries

Markedly short perineal length

Other cases in which failure to carry out an episiotomy will end in significant perineal rupture. The definitive rule is that there is no alternative for surgical judgment during delivery and common sense . <sup>(23)</sup>

#### TIMING OF EPISIOTOMY

If prematurely performed, causes haemorrhage unnecessarily from the wound site and might intervene considerably during the course between incision and delivery of the baby.

When performed too late, its inadequate in preventing lacerations.

When the head is seen to a diameter of 3 to 4 cm during a contraction, episiotomy is performed. When used along with forceps vaginal delivery, generally obstetricians practice an episiotomy after application of the forceps blades . <sup>(24)</sup>

## TYPES OF EPISIOTOMY

- 1. Median The line of incision is originates from the middle of the fourchette and extends posteriorly for about 2.5cms along the midline.
- 2. Mediolateral The incision is downwards and outwards starting from the midpoint of the fourchette either to left or right , further directed diagonally ended at about 2.5cms away from anus.
- 3. Lateral The incision begins from 1cm away from centre of the fourchette and further extended laterally. Caution to be followed regarding Bartholin's duct injury. It is obsolete now.
- 4. J shaped To avoid damage to the anal sphincter, the of the fourchette is incision begins in the centre and midline conducted posteriorly along the for approximately

1.5cm, then downwards and outwards along the 7'0 and 5'o clock positions. The drawbacks include improper apposition of the wound edges and edges tend to be puckered. It is obsolete too now.<sup>(25)</sup>



Figure 7 - Types Of Episiotomy

Of these above techniques only median and the mediolateral type of incision are usually used. In the exceptional cases involving third and fourth degree extensions ,midline incision episiotomy is superior. As it is associated with less blood loss, easy to repair , less postop pain and better results with healing anatomically aesthetic well.

## TECHNIQUES OF EPISIOTOMY

Preliminaries – The operative area i.e. the perineum is thoroughly painted with antiseptic solution (povidone - iodine) and draped with sterile cloth. <sup>(26)</sup> Infiltration - The proposed line of incision is infiltrated with local anaesthetic agent namely 10ml of 1% lignocaine.



Figure 8 -Infiltration With Local Anaesthesia

## INCISION

Before an incision is made, using left hand index and middle fingers, placed in vagina between the presenting art of the fetus and the posterior vaginal wall. Using a curved or straight blunt pointed sharp scissors an incision is made, of which one blade is placed in between the two fingers on the inside and the other

outside towards the skin. During height of uterine contraction the incision is taken after getting an idea of roughly an estimate regarding the extent of incision. <sup>(27)</sup>



Figure 9 - Performing Mediolateral Episiotomy



Figure 10 - Episiotomy Scissors

# STRUCTURES CUT

- Subcutaneous tissue and skin
- Perineal branches of pudendal vessels and nerves
- Fascia covering those muscles
- Superficial and deep transverse perineal muscles , bulbospongiosus and part of levator ani
- Posterior vaginal wall <sup>(28)</sup>

## EPISIOTOMY REPAIR

The three main factors that affect the outcome of the perineal repair are as follows :

- 1. The kind of the suture material being used
- 2. The technique of repairing the wound

#### 3. The skill of the obstetrician

#### PRINCIPLES OF REPAIR:

- Following delivery suture as soon as possible to reduce the possible blood loss and prevent risk of infection
- Good quality lighting is crucial to visualise and recognize the structures involved
- When in doubt seek expert advice for assistance
- In case of complicated restoration of anatomy , perform in operation theatre under anaesthesia
- Insert an indwelling per urethral catheter to prevent urinary retention for 24 hours in trauma involving the urethral and paraurethral area
- To guarantee that the wound is in appropriate anatomical alignment and that the aesthetic result is not compromised.
- A rectal inspection will be performed after the repair is completed to confirm that no suture material has been accidentally inserted through the rectal mucosa. <sup>(28)</sup>

## TIMING OF REPAIR

By and large for the most part general practice is to defer episiotomy repair until placenta has been delivered. The obstetrician can then emphasis on the symptoms of placental separation and birth. Another benefit is that episiotomy healing is not hindered or disrupted by the evident provision of delivering the placenta, especially if manual removal is required. <sup>(24)</sup>

#### **EPISIOTOMY REPAIR STEPS:**

There are numerous ways to repair an episiotomy wound as all the methods work around the principles of restoring anatomy and reducing blood loss and achieving haemostasis.



Figure 11- Identification of anatomical landmarks before episiotomy repair Any perineal trauma is routinely repaired in three layers. A continuous interlocking suture, commencing at the apex of the incision and terminating at the level of the fourchette with a knot, is traditionally used to seal the vaginal epithelium. Although the rationale behind employing an intern locking suture is to minimise shortening of the vaginal epithelium, there is no evidence to support this theory. In addition, interrupted sutures are used to approach the superficial and deep muscles, however some research suggests continuous suturing. Lastly the skin is approximated using vertical mattress or continuous subcutaneous sutures technique.<sup>(26)</sup>



Figure 12- Closure of mucosal layers starting from apex



Figure 13 - Closure of muscle layer

# CARE OF EPISIOTOMY WOUND

The women is advised to keep the episiotomy wound site dry and to be cleaned using soap and water from vulva towards anus i.e. anterior to posterior. To reduce the oedema and discomfort associated during the first few hours an ice bag is applied.

It is also said that using warm sitz bath after about 24 hours of delivery the moist heat helps in reducing local discomfort. Furthermore oral analgesics are routinely prescribed to curb the pain.

The healing of the episiotomy wound site is closely monitored. By about 3<sup>rd</sup> week the incision is healed firmly and is nearly asymptomatic. A poorly healed wound or excessive scar tissue can cause pain and is more sensitive in nature. Severe discomfort within the first day or so usually indicates a problem such as hematoma and after the third day infection. In cases where severe perineal , vaginal and rectal pain careful inspection and palpation is warranted.

The patient is taught about various exercises which could improve the tone of the perineal muscles. <sup>(29)</sup>

Certain studies state that usage of lavender oil essence after episiotomy can be helpful in reducing perineal discomfort and is preferred over routine usage of betadine for wound care. <sup>(30)</sup>

## DEGREES OF PERINEAL TEAR

First degree tear- Only skin injuries are involved.

Second degree tear – Injury to the perineal muscles is involved, but not the anal sphincter.

Third degree tear – Injuries to the perineum and the anal sphincter complex are involved.

3a : Approximately half of the thickness of the external anal sphincter has been torn.

3b: Approximately half of the thickness of the external anal sphincter has been torn.

3c: The internal anal sphincter has been torn.

Fourth degree tear- It involves injuries to the perineum including the whole Anal sphincter complex and also the anal epithelium <sup>(31)</sup>



Figure 14 – Perineal tear

## COMPLICATIONS OF EPISIOTOMY

The following are the immediate complications <sup>(32)</sup>:

1) Blood loss and vulval hematoma

- 2) Extension of incision ( $3^{rd}$  degree and  $4^{th}$  degree lacerations)
- 3) Infection including rare possibility of necrotizing fasciitis
- 4) Wound dehiscence

The following are the remote complications <sup>(32)</sup>:

- 1) Dyspareunia and perineal pain
- 2) Anovaginal and rectovaginal fistulas
- 3) Anal incontinence
- 4) Epidermal inclusion cyst
- 5) Scar endometriosis

#### WOUND HEALING

Conventionally the wound healing and its related physiology is segmented in three broad phases which are Inflammation, proliferation and remodelling. <sup>(33)</sup>

Phase I: Inflammation (Onset of Injury to Days 4–6)

The first phase of healing of wound consists of hypoxic and ischemic environment which is filled with macrophages, neutrophils and platelets. After tissue injury within a few moments to limit any further injury the body itself responds. Potent vasoconstrictors like thromboxane  $A_2$  and prostaglandins  $F_{2\alpha}$ are immediately released to after damage to cell membrane. Further blood loss is reduced as the vessels are clamped shut.

Upon damage to the blood vessels, the vascular epithelium gets exposed which is a potent initiator for coagulation cascade. Migration of platelets occur immediately followed by Von Willebrand's factor, Resulting in plugging of defects in the vasculature. The blood clot is formed by platelets, thrombin, fibrin, collagen, fibronectin and complements.

Lastly the monocytes on stimulation form macrophages which is crucial for angiogenesis, Cellular signalling, fibroblast development with neutrophils and

keratinocyte formation that help in consuming bacteria and the necrotic tissue at the wound.

#### Phase II: Proliferation (Days 4–14)

The next stage in wound healing involves rapid reconstruction of new tissue to replace the old dead tissue . The macrophages secrete nitrous oxide and the vessels that were constricted as result of preventing blood loss slowly dilate to support the influx of new cells. The epithelial cells at the skin edge proliferate fuelled by growth factors to form an eschar and migrate to recreate a protective layer over.

At the same time new capillaries form and expand the previously existing networks. At this stage angiogenesis is critical. The formation of granulation tissue occurs. From the surrounding intact tissue the fibroblasts are recruited and they synthesize to deposit collagen in the tissue. It is further amplified by both paracrine and autocrine cascades , and a mixture of type III collagen , fibronectin and glycosamino glycans are laid out in the wound site.

Phase III: Maturation and Remodelling (Week 1–Year 1)

The last stage of wound healing includes the evolution of the above said matrix into a much refined and ordered structure called collagen complex.

Over maturation and overzealous refining causes keloid formation of the tissue and at the same time inability to mature also causes weak and ineffective scar tissue. To minimize the amount of collagen the myofibroblasts of the wound begin to shrink and cause contraction at the site so as to minimize the amount of collagen deposition requirement. Furthermore contraction leads to formation. Of crosslinks of collagen fibres and increase in strength.

This collagen deposition goes on for about 4 to 6 weeks. The collagen fibrils run parallel to the surface of the wound. When maturation of wound occurs these

fibres get thicker and reorient in such a fashion so as to minimize stress. During the postoperative period this is reflected as an increase in tensile strength of wound.

The wound strength differs as time progresses as follows at first week its only 3% and at 3<sup>rd</sup> week it is at 30% of its final strength and at 3 months and beyond it is approximately 80% of its final strength. However wound site tissue never gains full strength as comparable to uninjured tissues.

Inflammatory phase

**Proliferative phase** 

Maturation phase





Figure 15 - Stages of wound healing

# **EFFECT OF FOREIGN BODIES AND EXCESS INFLAMMATION ON WOUND HEALING**

Any presence of foreign body at the wound site causes excessive tissue inflammatory response which could cause decrease in lowering the body defence mechanisms towards infection, as well as interference with the stage of proliferation of wound healing and lastly leads to decreased wound strength as a result of excessive scar tissue. Due to the presence of foreign body like suture material inflammatory reactions would persist as long as they prevail within the tissue. The reaction degree depends mostly by and large on the physical characteristics and chemical nature of the suture materials used.<sup>(34)</sup>

#### AND OF CLASSIFICATION CHARACTERISTICS SUTURE MATERIAL

As old as 4000 years ago the relationship between wound closure biomaterials was established when linen was used as a suture material. Various materials were used as suture materials including gold, silver, iron, steel, dried gut, tree bark, animal hair and various other plant fibres and newly a much wider synthetic compositions have been emerging. <sup>(35)</sup>

Nevertheless with all the exhausting and extensive experienced research works with wound closure materials, no study nor surgeon has yet to identify the perfect suture material with properties such as:

- Minimal reactivity to tissues
- Comfortable handling by surgeon
- Adequate strength for the time needed for tissues to approximate
- Not suitable for growth of microorganisms and can be easily sterilized
- Non allergic
- Non- carcinogenic <sup>(35)</sup>

There are various ways to Classify suture materials based on the following:

- Size of suture material
- Tensile strength
- Absorbing capacity
- Filament type
- Pliability and stiffness

Size of suture material:

- Suture materials can be classified based on size and range is defined in terms of two standards i.e. The United States Pharmacopoeia (USP) and the European Pharmacopoeia
- For synthetic suture more commonly listed in terms of USP. The USP is a combination of 2 numerals -a 0 and another number other than 0 (like 2-0 or 2/0). The first number defines the diameter as in the higher the number smaller the diameter.
- In terms of diameter, the USP standard code differs between collagen and synthetic sutures, while the EP standard corresponds to the same minimum diameter regardless of material. The tensile strength of all sutures increases as the size increases, as projected.

# TENSILE STRENGTH

- Suture material is used in surgery to alleviate disruptive forces on healing tissues.
- Each suture material has a known tensile stress, which is most easily described for a given suture size as its failure or break load. This is the weight in pounds or kilogrammes required to cause the suture to tear. This measure is typically described in two forms: straight pull and knot pull.
- Both of these measurements are listed as in vitro values and represent only the sutures' immediate out-of-the-package strength. <sup>(36)</sup>

Suture	Straight-Pull Strength	Knot - Pull Strength
	(kilogram force)	(kilogram force)
Chromic surgical gut	4.11	2.05
Polydioxanone	4.89	3.34
Coated polyglactin910	6.93	3.63
Poliglecaprone 25	7.26	3.67

Figure 16 – Tensile strength of suture materials

#### ABSORBABLE VERSUS NONABSORBABLE (37)

- Almost all foreign bodies cause a tissue reaction that impedes wound healing. The longer a suture material remains in the body, the more likely it is to act as a nidus for adverse tissue reactions that may delay or disrupt normal wound healing.
- As a result, the ideal suture material can maintain sufficient strength during the healing process and dissolve with minimal an associated inflammatory response.
- Suture materials are graded as absorbable or nonabsorbable in terms of long-term performance depending on whether they end up losing their

entire tensile strength within 2 to 3 months or maintain their entire strength for longer than 2 to 3 months.

- As the sutures dissolve, all absorbable sutures go through two phases of absorption. First, there is a decrease in tensile power, and second, the suture mass decreases.
- Dating back to the 1930s, the sutures of preference were surgical gut (collagen sutures created from sheep or cow intestines) and silk. The introduction of newer synthetic fibres such as nylon, polyester, and polypropylene around the time of World War II broadened the nonabsorbable suture options, while plain and chromic gut remained the only easily absorbed suture options.
- Surgical gut is mainly of two types: simple and chromic. The basic initial extraction is the same for both varieties. The submucosa of sheep intestines or the serosa of cow intestines are cut into longitudinal ribbons and formaldehyde is applied. Numerous ribbons are therefore woven into strands before being dried, beaten down, and brushed to the appropriate suture size The untreated substance that results is known as simple gut. As plain gut is tanned even more in a chromium trioxide bath, it becomes chromic gut. The chromium treatment postpones the absorption of the chromic intestine, extending its tensile properties much longer than plain gut.
- While plain & chromic gut suture materials indeed provided the medical community excellently for several years and millions of operations, the mere existence of the material's manufacturing and composition renders this suture material a little under ideal even now.
- Firstly, the grinding and polishing of the warped multifilament suture results in an unpredictability of weak points and fibril damages, which leads to the sutures' typical wear and tear with use. Furthermore, due to a certain processing conditions, measurable intensity is difficult to achieve.
- Quite significantly, since surgical gut is a foreign protein, these are damaged and consumed primarily by proteolytic enzymes from phagocytes and some other cells, resulting in a rather predictable absorption rate and an even stronger tissue reaction than recent, synthetic surgical sutures.
- With the advent of synthetic absorbable sutures in the early 1970s, a new era of suture material began. These substances vastly outnumber natural products in terms of strength and degradability within biologic environments since they can be manufactured with precisely regulated manufacturing process with consistent chemical composition. Furthermore, because those materials are nonproteins, they typically induce less violent tissue reactions, which promotes faster healing of wounds and power.
- Polyglycolic acid-polyglycolide and glycolide-l-lactide random ۲ copolymer or polyglactin 910 were the very first commercially available absorbable sutures. Both are generated by melt spinning chips. To boost dimensional stability and prevent contraction, the fibres are extended to several hundred times of their initial size and heat-set. Almost all of these products are just too stiff in bigger sizes to be useful as sutures due to the high density of ester functional groups. As a result, individual smaller fibres are braided into final multifilament strands of varying sizes, resulting in a product with consistent absorption and endurance profiles as well as suitable handling properties. Following extra treatment, the sutures are sterilised with ethylene oxide and sealed in an inert gas to prevent the suture from just being altered by ambient moisture.
- A purple colourant is applied to certain Polyglactin 910 to improve its appearance against wound tissues.
- Since these synthetic fibres are hydrolysed in vivo, they cause less inflammation than their natural protein analogues.

- Amid these advancements, a synthetic monofilament suture that was absorbable was still needed. This vacuum was filled inside the 1980s with the advent of newer polymers. Poly-p-dioxanone or polydioxanone and poly(glycolide-trimethylene carbonate) copolymer or polyglyconate are indeed absorbable monofilament sutures with the predictable strength and absorption conditions of their earlier polymer cousin albeit with more suitable versatility that enables for a monofilament structure.
- When suture technology progressed, surgeons tried to improve synthetic absorbable suture materials in order to expand their applications. To address the evident need for a polyglycolic acid-based suture with a shorter absorption profile, a fast-absorbing variant of conventional polyglactin 910 suture material pre-treated with ionising rays to expedite hydrolysis was developed in 2003. This newest suture material has a median absorption of 42 days as a result of its pre-treatment.

#### ABSORPTION RATES OF ABSORBABLE SUTURES – Figure 17

Suture	Time to 50%	Time to	Time to
	Loss of Tensile	Complete	Complete
	Strength (days)	Loss of Tensile	Mass Absorption
		Strength (days)	(days)
	2.5	14.01	70
Plain surgical gut	3-3	14-21	/0
Fast absorbing	5	14	42
coated	5	14	42
polyglactin 910			
Poliglecaprone	7	21	90-120
(MonocrylTM)			
Chromic surgical	7-10	14-21	90-120
gut			

### **MULTIFILAMENT VERSUS MONOFILAMENT**

- The use of more than one fibre in the production of a single finished strand of suture is referred to as multifilament.
- There are no benefits of using a multifilament suture over a monofilament suture in terms of wound healing. Multifilament sutures cause more microtrauma than monofilament sutures as they move through tissues. Multifilament sutures often elicit a stronger inflammatory response.
- Nevertheless, existing multifilament sutures usually have better handling properties and material stability than comparable solid monofilament materials.

### STIFFNESS AND FLEXIBILITY

- Suture stiffness and flexibility, while often ignored as main characteristics, can be just as important as strength and absorption since these traits decide how a material handles or feels. The stiffness of the suture decides whether it is soft or heavy, whether it has memory or recoil, and how easily knots can be tied.
- Moreover, stiffness is synonymous with the inclusion or exclusion of mechanical irritation of the suture as a result of its ability or inability to conform to the layout of the surrounding tissues.
- In general, monofilament suture materials to increase bending stiffness than multifilament, braided suture materials at any given scale. In this regard, natural multifilament twisted sutures, such as chromic catgut, behave more like monofilaments than braided multifilament sutures.

### Selection Of Suture Material For Perineal Repair<sup>(38)</sup>

Before selecting a suture material, surgeons must consider the tissue and physiologic milieu into which the suture will be inserted, in addition to considering the physical properties and characteristics of the various available suture materials.

In general, the suture-holding strength of most soft tissues is determined by the amount of fibrous tissue present. Sutures are therefore well retained by skin and fascia, but not by brain and spinal cord tissue.

Additionally, healthy tissues appear to sustain sutures better than inflamed, edematous tissues.

Wound healing is a mechanism that occurs in any given tissue. In this interim time, wound closure biomaterials are used to provide supplemental support for the tissues.

Nevertheless, since all materials cause some degree of unwanted inflammatory reaction, striking a balance between strength and inflammation is critical when selecting a suture for a specific tissue closure.

Suturing products for the repair of obstetrical perineal lacerations have received a fair amount of attention. Obstetrical lacerations heal well regardless of materials or technique due to the increased vascularity in the peripartum phase. In the perineum, an absorbable suture material is the best choice.

While collagen sutures, such as chromic gut, have performed admirably for decades, as previously stated, newer synthetic absorbable suture materials elicit less inflammatory tissue response than chromic gut, and thus it has been hypothesised that the use of synthetic materials in perineal repairs may result in less postpartum pain.

However, since synthetic materials degrade at a slower pace, some have expressed concern that residual synthetic suture material may cause problems for patients weeks after their lacerations had healed, as well as act as a nidus for infection. Besides that, some authors have raised questions that more rigid monofilament sutures can "poke through" their skin's edges may irritate patients.

These theories were tested in a number of randomised trials that Kettle and Johanson reviewed for the Cochrane Database in 2001. Their research, which included experiments using a variety of synthetic suture products, suggested that using Dexon and Vicryl for perineal restoration after childbirth is correlated with less short-term pain but higher rates of suture removal as opposed to chromic catgut.

After that study, fast-absorbing polyglactin 910 has been developed, and two trials have shown reduced postpartum pain and faster commencement of sexual activity without a difference in wound degradation or remaining suture material as fast-absorbing polyglactin 910 was compared to chromic gut. Fast-absorbing polyglactin 910 appears to be the rational option nowadays for repairing of obstetrical perineal lacerations based on these trials, its handling characteristics, and the theoretical advantages of this newer material.

#### AIMS OF THE STUDY

To compare and evaluate the properties and characteristics of fast- absorbing polyglactin 910 versus chromic catgut suture material for episiotomy wound repair

### **OBJECTIVES**

To compare the fast-absorbing polyglactin 910 versus chromic catgut sutures in the repairing of episiotomy wound

- 1. Postpartum perineal pain and need for analgesia
- 2. Nature of wound healing

### **METHODOLOGY**

The study will be conducted at B.L.D.E (DEEMED TO BE UNIVERSITY) SHRI B.M. PATIL MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE. This is a randomised, controlled trial with two groups of patients chosen at random according to the inclusion criteria.

### **SOURCE OF DATA**

This is a Randomized comparative study.

All the patients who fulfil inclusion criteria will be studied. Consents will be taken once the patient is admitted . After performing mediolateral episiotomy Block Randomisation with Size 1 will be used to allocate the women into group I or group II.

Polygalactin 910 (rapid absorbing) 2-0 or chromic catgut 1-0 are used to stitch the episiotomy wound. A conventional three-step procedure is used to repair episiotomies. A continuous interlocking suture is used to suture the vaginal mucosa, while an intermittent suture is used to repair the perineal muscle. In Group 1, the skin is closed with a mattress suture, whereas in Group 2, the skin is closed with subcuticular sutures.

In terms of age, parity, presentation, and gestation duration, both groups are compared. Patients in both groups are given a single dose of antibiotic (ceftriaxone 1 gm) before to the operation, and analgesics such as diclofenac sodium or ibuprofen are administered after suturing.

Outcomes:

The following are the primary outcome metrics that were recorded:

After 24 to 48 hours postpartum : Perineal pain perception along with any discomfort , swelling at perineum , tightness at site of wound Days 10 to 14 days postpartum : Perineal pain, wound discharge, disruption or

dehiscence of any extent

Six weeks after postpartum: Wound healing complete/incomplete ,removal of an residual unabsorbed suture

The pain is assessed using a ruler and a visual analogue scale (VAS); the score is calculated by measuring the distance (mm) as none, mild, moderate and severe; the cut off points on VAS are as follows: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).

Fever, throbbing pain in the perineum, edema, and drainage from the area are all clinical indicators of a wound infection.

### **INCLUSION CRITERIA -**

- All women with episiotomy wound
- Any 2<sup>nd</sup> degree perineal lacerations

### **EXCLUSION CRITERIA -**

- Episiotomy that are extended due to instrumental deliveries
- Anaemia
- Diabetes
- PROM or PPROM for more than 24 hours

#### Investigation done for all the patients -

- Complete blood count
- Platelet count
- Urine routine
- Random blood sugar

#### **REVIEW OF LITERATURE**

- After being described by Ould in as early as 1741, episiotomy was routinely given in a mediolateral fashion in all nulliparous births in order to protect the fetal head from trauma and also the pelvic floor from extreme lacerations.<sup>(45)</sup>
- In the Wear Berkshire perineal management trial, one thousand women were allocated to one of the two groups-one with restrictive episiotomy and another with liberal episiotomy.
- The restrictive group experienced more perineal tears and labial tears. There was no difference between the two groups in terms of perinatal mortality,maternal pain or urinary symptoms at 10 days and three months postpartum. Women who had perineal tears in the restrictive group also resumed intercourse 1 month post delivery. Hence this study says there is little support for liberal episiotomy, since there was not much significant difference. <sup>(46)</sup>
- A Turkish trial was conducted in 2015-16 studying the long term and short term consequences of episiotomy. The current meta analysis and studies assessed showed that liberal use of episiotomy did not decrease the incidence of pain,dyspareunia,sexual dysfunction,and pelvic floor damage. Hence this study concludes that episiotomy can be restrictive rather than routine use.<sup>(45)</sup>
- The largest study comparing long term effects was conducted in 1996 in France, in two hospitals with a diverse policy for

episiotomy. After 4 years the participants were mailed a questionnaire regarding variables like anal incontinence, urinary incontinence, dyspareunia, and pelvic pain. It showed that anal incontinence was less prevalent in the restrictive group. Logistic regression confirmed that routine episiotomy was associated with two times more risk for anal incontinence than the restrictive group.<sup>(45)</sup>

- In a study titled the effects of episiotomy on pelvic floor function after vaginal delivery, about 500 women were randomly allocated for episiotomy versus spontaneous delivery associated with first and second degree perineal lacerations. No difference was observed in terms of perineal pain, anal or urinary incontinence, but there was higher incidence of perineal pain and dyspareunia in the episiotomy group. <sup>(47)</sup>
- In a study conducted in the rural population of India comparing the continuous and intermittent suturing , in about 200 term women having an episiotomy, the results showed lesser pain, less no. of suture materials and lesser time for suturing in the continuous technique and hence which is also cost and time effective.<sup>(48)</sup>
- Dash et al conducted a study in Behrampur medical college , Odisha in 2013, comparing two techniques of suturing- continuous and intermittent and according to their study, the continuous suturing technique was better with lesser time required,lesser suture material required, and also lesser pain.<sup>(49)</sup>
- Kettle et al also conducted a similar study and found out lesser pain in the continuous suturing group. Almeida and Reico also compared the two techniques and found lesser pain in the continuous group.<sup>(9)</sup>

- They did a meta analysis of about 16 trials done in this aspect and found out that the continuous subcuticular suturing technique was associated with lesser pain on 10th postnatal day, lesser need for suture removal compared to the intermittent suturing, but no difference was observed in terms of dyspareunia and resuturing of the wound.
- Mota R and Costa F differed in that they compared subcuticular suturing with adhesive glue for skin sutures and found lesser pain when glue was used instead of sutures.<sup>(50)</sup>
- This study was done over a 100 women to compare mainly pain long term in the two groups. Other variables measured were secondary outcomes like duration of repair, technical difficulties during repair, wound complications observed postpartum, and regaining of sexual function in 30 days postpartum. There was no difference in the two groups in terms of pain during the procedure, technical difficulties, wound outcome. The glue repair took lesser time about four minutes lesser and had lesser pain postpartum.
- The Cochrane meta analysis rewiew also says that there is less pain and lessertime taken in the continuous technique.<sup>(8)</sup>
- In a study comparing overlap repair vs end to end repair, the overlap repair was better in that there was lesser fecal incontinence and dyspareunia, after 1 year follow up.<sup>(51)</sup>
- In another study conducted in 2014 in Cuttock,Odisha- the continuous method is better in terms of dyspareunia,lesser time taken for suturing, and he added a point that for a new trainee to suture the episiotomy wound, the continuous method was easier and required a shorter learning curve.(52)
- In KIMS, Karad, a study was done among 100 women divided into two groups for the two techniques of suturing. Episiotomy was

given in view of shortening duration of 2nd stage of labour, preventing fetal head injuries, preventing perineal tears and hence incontinence. The study reported lesser incidence of pain in the continuous suturing than the intermittent technique.<sup>(53)</sup>

- Moving on to studies comparing suture materials, newer • replaced monofilament synthetic suture materials have the traditionally used catgut for episiotomy suturing. In a study conducted in Dhavangare, use of vicryl resulted in lesser pain and better wound healing than catgut.<sup>(40)</sup>
- The Cochrane database comparing various trials comparing catgut and other synthetic suture materials , like standard synthetic,rapidly absorbing synthetic sutures and glycerol impregnated sutures, concluded that catgut causes more short term perineal pain than synthetic suture materials.<sup>(9)</sup>
- The Ipswich Childbirth study, which was a randomized comparison between Polyglactin and catgut, conducted in 1992-1994, concluded that the polyglactin group required lesser analgesics and there was less pain at 10 days postpartum, compared to the catgut group. The only disadvantage was that out of 200 people sutured using polyglactin,one needed resuturing.<sup>(9)</sup>
- In a study conducted in the institute of social obstetrics and government Kasturba Gandhi hospital in Chennai in 2012, they concluded that there was lesser pain postpartum and lesser wound dehiscence in the polyglactin group compared to the catgut group,but there was no significant difference in dyspareunia between both.<sup>(54)</sup>
- In 2015, Abdullah, Iqbal, Sohail conducted a study at the Services Hospital Lahore, comparing the incidence of pain after episiotomy in Primigravidas. They conducted this study on 100 women. The basis

of their study was that vicryl rapide or polyglactin had lesser tissue reaction was absorbed by hydrolysis,in comparison to catgut which was manufactured using collagen, causes tissue reaction and is degraded by proteolytic reaction and phagocytosis. <sup>(44)</sup> The results of their study was that use of vicryl rapide was better for episiotomy.

- Al Khafaji compared two different methods of episiotomy and published a study in 2005-06. It was conducted on 300 women where, 100 women were sutured using vicryl and 200 with chromic catgut and examined at 5 and 10 days postpartum for pain and wound healing. In majority of women the indication for episiotomy was nulliparity with a tight perineum . pain on the 5th day was lesser in the vicryl group. This group had a different result in that wound infection was lesser with vicryl but with mattress technique suturing. <sup>(44)</sup>
- An article in the British Journal of midwifery explains about the material we have used in my study-the vicryl rapide. Materials such as Dexon and Vicryl cause minimal tissue reaction, but takes about 2-3 months to degrade. But the newer Vicryl Rapide or Polyglactin has smaller components of vicryl and degrades more quickly- after 5 days the tensile strength is reduced by 50 % and after 14 days all tensile strength and tension is lost.<sup>(55)</sup>
- In a study conducted in MVJ medical college Bangalore, comparison between continuous and intermittent suturing showed that the continuous technique was associated with lesser time taken, lesser material used, lesser pain postpartum, and lesser need for analgesics.<sup>(56)</sup>
- In a randomized controlled trial conducted by Kettle , Hill, Jones, Reynolds- comparing the two techniques of suturing and also the two materials used, they stated that the continuous technique of

suturing causes lesser pain on the 10th postpartum day compared to intermittent technique and the polyglactin material obviates the need for suture removal 3 months postpartum than the catgut material.<sup>(8)</sup>

• Kurien Joseph et al conducted a study in 2008, at the railway hospital among 150 patients comparing the three suture materialschromic catgut, polyglactin standard and polyglactin rapide. The patients were divided in three groups a prospective randomized trial done. The study showed distinctive advantage of polyglactin or vicryl rapide over the standard vicryl and catgut materials in terms of postpartum pain, need for analgesics, wound healing, need for resuturing.<sup>(41)</sup>

#### **RESULTS**

For episiotomy wound healing, 200 women were randomly assigned to one of two groups: 100 received chromic catgut No.1-0 and the other 100 received Fast absorbing polyglactin 910 No.2-0.

There was no loss of follow-up for any of the participants after delivery. The results are as follows.

Age (Years)	CATGUT	VICRYL				
	No. of patients	nts Percentage No. of patier		Percentage		
< 20	3	3.0	9	9.0		
20 - 24	52	52.0	63	63.0		
25 - 29	32	32.0	23	23.0		
30 - 34	10	10.0	5	5.0		
35+	3	3.0	0	0		
Total	100	100.0	100	100.0		

Table 1: Age distribution of study population



As depicted here, majority of the patients belonged to 20-24 years of age in both the groups 52 % in Chromic Catgut and 63% in Fast absorbing polyglactin 910. But it was not statistically significant.

### **TABLE: 2 BMI DISTRIBUTION OF STUDY POPULATION**

BMI (Kg/m2)	CATC	JUT	VICH	RYL	
	NO OF DATIENTS	DEDCENTAGE	NO OF PATIENTS	DEDCENTAGE	
	TATIENTS	TERCENTAGE	TATIENTS	TERCENTAGE	CIII
<18					SQUARE
	23	23	24	24	TEST
18-25	72	72	67	67	X2 = 1.344
26+	5	5	9	9	P = 0.5107
TOTAL	100	100	100	100	



#### **TABLE 3 : GESTATIONAL AGE DISTRIBUTION IN STUDY POPULATION**

					CHI SQUARE
POG	CATGUT		VICRYL		TEST
	NO OF		NO OF		
	PATIENTS	PERCENTAGE	PATIENTS	PERCENTAG	E
<37	2	2	6	6	X2 = 2.083
37+	98	98	94	94	P = 0.1483
TOTAL	100	100	100	100	



As seen here the gestational age distribution the poupulation in both groups reamied to be term in majority namely 98% in catgut and 94% in vicryl group. The difference was not significant statistically (p value = 0.1483)

# TABLE : 4 DISTRIBUTION OF GRAVIDITY STATUS IN STUDYPOPULATION

GRAVIDA	CATGUT	VICRYL	
	PERCENTAGE	PERCENTAGE	CHI SQUARE TEST
1	46	45	X2 = 3.070
2	42	43	P = 0.5461
3	10	11	
4	2	0	
5	0	1	



When compared with regards to the gravidity status of both the groups , majority of them belonged to primigravidae ; 46 % in group 1 and 45 % in group 2. The difference was not staistically significant in both the groups.

## Table : 5 DISTRIBUTION OF PARITY STATUS IN STUDYPOPULATION

PARITY	CATGUT	VICYRL	
			CHI SQUARE
	PERCENTAGE	PERCENTAGE	TEST
0	61	56	X2 = 5.101
1	33	43	P = 0.0780
2	6	1	



When compared with regards to the parity status of both the groups , majority of them belonged to primigravidae ; 61 % in group 1 and 56 % in group 2. The difference was not staistically significant in both the groups.

# Table : 6DISTRIBUTION OFLIVINGISSUESINSTUDYPOPULATION

LIVING	CATGUT	VICYRL	
			CHI SQUARE
	PERCENTAGE	PERCENTAGE	TEST
0	61	61	X2 = 1.923
1	35	38	P = 0.3823
2	4	1	



The number of living children in both the groups were surprisingly amounting to the same 61% of having a single child in previous pregnancy although this was not statistically significant.

# Table : 7 DISTRIBUTION OF DEATHS IN PREVIOUS PREGNANCIESIN STUDY POPULATION

DEAD	CATGUT	VICYRL	
			CHI SQUARE
	PERCENTAGE	PERCENTAGE	TEST
0	98	95	X2 = 1.332
1	2	5	P = 0.2484



Among both the study groups majority of them no deaths in the previous pregnancies . An insignificant amount of the study population i.e. 5% in group 1 and 2 % in group 2 had fetal deaths in the past pregnancies. This was not statistically significant upon comparison.

## TABLE : 8 DISTRIBUTION OF ABORTIONS IN PREVIOUSPREGNANCIES IN STUDY POPULATION

ABORTION	CATGUT	VICYRL	
			CHI SQUARE
	PERCENTAGE	PERCENTAGE	TEST
0	79	78	X2 = 1.006
1	19	19	P = 0.7997
2	2	2	
3	0	1	



Among both the study groups majority of them no abortions in the previous pregnancies . A minor amount of the study population i.e. 22% in group 1 and 21 % in group 2 had fetal deaths in the past pregnancies. This was not statistically significant upon comparison.

# TABLE : 9 PERINEAL TEARS ENCOUNTERED IN STUDYPOPULATION

PERNIEAL			
TEARS	CATGUT	VICYRL	
			CHI SQUARE
	PERCENTAGE	PERCENTAGE	TEST
PRESENT	3	5	X2 = 0.5282
ABSENT	97	95	P = 0.4705



By and large of the population when compared in both the groups had no perineal tears as a very insignificant amount i.e. 3 % in Catgut group and 5% in Vicryl group were encountered with perineal tears during delivery. This was not statistically significant upon evaluation.

#### TABLE : 10 ANALGESICS USED IN STUDY POPULATION

ANALGESIC	CATGUT	VICYRL	
	DEDCENTACE	DEDCENTACE	CHI SQUARE
	PERCENTAGE	PERCENTAGE	IESI
DICLOFENAC	35	25	X2 = 2.381
IBUPROFEN	65	75	P = 0.1228



After childbirth two different anaglesics were used oral preparations namely Diclofenac sodium and Ibuprofen and were compared with regards to their effectiveness. Although majority of them received Ibuprofen namely 65% in Catgut group and 75 % in Vicryl group but this was not significant statistically.

## TABLE : 11PERINEAL PAIN PERCEPTION FOLLOWING 24 TO48HRS POSTPARTUM

AFTER 24 TO 48	HRS		
PERINEAL			
PAIN	CATGUT	VICYRL	
	PERCENTAGE	PERCENTAGE	CHI SQUARE TEST
MILD	26	45	X2 = 11.551
MODERATE	56	49	P = 0.0031
			HIGHLY
SEVERE	18	6	SIGNIFICANT



Perineal discomfort can be mild, moderate, or severe 24 to 48 hours after birth. In comparison to Group 1, mild and moderate pain perception was as high as 94 percent in Group 2, while severe grade pain was more prevalent in Group 1, with 6 percent out of 24 percent of total severe grade pain in both groups. With a P value of 0.0031, this was statistically significant.

## TABLE : 12PERINEAL PAIN AFTER 24 TO 48 HRS AFTERDELIVERY ACCORDING TO VAS SCALE IN STUDY POPULATION

FOLLOWUP	OF 24 TO 48 HRS		
PERINEAL P	PAIN		
VAS SCALE	CATGUT	VICRYL	
	PERCENTAGE OF PATIENTS	PERCENTAGE OF PATIENTS	CHI SQUARE TEST
0	0	0	X2 = 20.584
1	2	2	P = 0.0083
2	17	23	HIGHLY SIGNIFICANT
3	7	20	
4	15	18	
5	18	20	
6	19	12	
7	10	1	
8	10	3	
9	2	1	



After 24 to 48 hrs following delivery perineal pain was assessed using VAS scale ranging from 0 to 9 in the increasing order of pain perception. The results show that mild to moderate degree of pain is perceived majorly in cases of Group 2 while higher degree of pain is experienced more in cases of Group 1 individuals this is supportive of the evidence that Vicryl causes lesser pain than Catgut. This was statistically highly significant as p value is 0.0083.

### TABLE : 13NOOFAFTER 24TO48HRSAFTERDELIVERYDOSAGES OF ANALGESICS IN STUDY POPULATION



After 24 to 48 hours of delivery the number doses used in both the Groups were compared and the results show that in Group 1 show minimal requirement of dosage of 3 while in Group 2 it was 2 doses. 67% of women required 3 doses of analgesics whereas only 52% required the same in case of Group 2. Only 1% patients in either groups required 5 doses of analgesics. This was statistically highly significant as p value is <0.0001.

## TABLE : 14COMPARISON OF THE DISCOMFORT/TIGHT SUTURESEXPERIENCED BY BOTH GROUPS AT 24 – 48 HRS.



Patients were also questioned about discomfort/tight sutures 24 to 48 hours after delivery, and 54 percent of those in the catgut group said yes, whereas just 17 percent of those in the Vicryl group said yes. Because the p value was 0.0001, this was statistically significant.

## TABLE 15: COMPARISION OF THE INFECTION RATE IN BOTHGROUPS AFTER 24 TO 48 HOURS POST PARTUM

FOLLOWUP 24 TO 48 HRS			
INFECTION	CATGUT	VICRYL	CHI SQUARE TEST
	PERCENTAGE OF	PERCENTAGE OF	
	PATIENTS	PATIENTS	N/A
YES	0	0	
NO	100	100	

After 24 to 48 hours no patient in either group had any symptoms or signs of infection.

## TABLE : 16PERINEAL PAIN AFTER 10 TO 14 DAYS AFTERDELIVERY IN STUDY POPULATION

FOLLOWUP OF	10 TO 14 DAYS			
PERINEAL PAIN				
	CATGUT	VICRYL		
	PERCENTAGE OF	PERCENTAGE OF		CHI SQUARE
	PATIENTS	PATIENTS		TEST
NO	26		61	X2 = 62.735
MILD	23		37	P = < 0.0001
				HIGHLY
MODERATE	39		2	SIGNIFICANT
SEVERE	12		0	



Perineal discomfort can be mild, moderate, or severe 24 to 48 hours after birth. At the end of 10 to 14 days postpartum, 26 percent of patients in Group 1 had no pain at all, whereas 61 percent of patients in Group 2 had no pain at all. The low level of pain perception was 37 percent in Group 2 compared to 23 percent in Group 1, while the high grade pain was only 12 percent in Group 1. P = 0.0001 indicated that this was statistically significant.

### TABLE : 17PERINEAL PAIN AFTER 10 TO 14 DAYS AFTERDELIVERY ACCORDING TO VAS SCALE IN STUDY POPULATION

FOLLOWUP OF 10 TO 14 DAYS			
PERINEAI	L PAIN		
VAS SCALE	CATGUT	VICRYL	
	PERCENTAGE OF PATIENTS	PERCENTAGE OF PATIENTS	
0	26	61	
1	2	2	
2	15	20	
3	5	15	CHI SQUARE
4	28	1	X2 = 66.26 P < 0.0001
5	11	1	HIGHLY
6	1	C	
7	11	C	
8	1	C	



After 10 to 14 days following delivery perineal pain was assessed using VAS scale ranging from 0 to 9 in the increasing order of pain perception. The results show that mild to moderate degree of pain is perceived majorly in cases of Group 2 while higher degree of pain is experienced more in cases of Group 1 individuals this is supportive of the evidence that Vicryl causes lesser pain than Catgut. In both groups, however, no women reported increased levels of discomfort. Because the p value was 0.0001, this was statistically significant.

### TABLE : 18COMPARISON OF THE DISCOMFORT/TIGHT SUTURESEXPERIENCED BY BOTH GROUPS AT 10 -14DAYS

FOLLOWUP 10 to 14 days			
TIGHT/UNCOMFORTABLE			CHI SQUARE
SUTURES	CATGUT	VICRYL	TEST
	PERCENTAGE OF	PERCENTAGE OF	
	PATIENTS	PATIENTS	X2 = 8.589
YES	23	8	P = 0.0034
			HIGHLY
NO	46	83	SIGNIFICANT



Patients were also asked about discomfort/tight sutures 10 to 14 days after birth, and 54 percent of those in the catgut group said definitely, whereas just 17 percent of those in the Vicryl group said indeed. Because the p value was 0.0001, this was statistically significant.

## TABLE : 19COMPARISION OF THE INFECTION RATE IN BOTHGROUPS AFTER 10 – 14 DAYS POST PARTUM

FOLLOWUP	10 - 14 DAYS		
INFECTIO			
Ν	CATGUT	VICRYL	
	PERCENTAGE OF	PERCENTAGE OF	CHI SQUARE
	PATIENTS	PATIENTS	TEST
YES	0	0	X2 = 1.005
NO	100	100	P = 0.3161

After 10 - 14 days no patient in either group had any symptoms or signs of infection.

## TABLE : 20COMPARISION OF THE WOUND GAPING IN BOTHGROUPS AFTER 10 – 14 DAYS POST PARTUM

FOLLOWUP 10 - 14 DAYS			
GAPING	CATGUT	VICRYL	
	PERCENTAGE OF	PERCENTAGE OF	CHI SQUARE
	PATIENTS	PATIENTS	TEST
YES	14	4	X2 = 6.105
NO	86	96	P = 0.0135



After 10 -14 days postpartum 14 % women had wound gaping in Group 1 and 4 % in Group 2. Despite the fact that Group 1 included more patients with wound gaps, the p value of 0.0135 was not statistically significant.

## TABLE : 21 COMPARISION OF RESIDUAL PERINEAL PAIN 6WEEKS POST PARTUM

FOLLOW UP	6 WEEKS LATER		
RESIDUAL			CHI SQUARE
PAIN	CATGUT	VICRYL	TEST
	PERCENTAGE OF	PERCENTAGE OF	
	PATIENTS	PATIENTS	X2 = 5.128
YES	5	0	P = 0.0235
			HIGHLY
NO	95	100	SIGNIFICANT



After 6 weeks postpartum, patients in both groups were asked about residual pain, with only 5% in Group 1 reporting mild discomfort and none in Group 2. Because the p value was 0.0235, this was statistically significant.

## TABLE : 22 COMPARISION OF ANY RESIDUAL SUTURESFOLLOWED BY 6 WEEKS POST PARTUM

FOLLOW UP 6 WEEKS LATER			
			CHI SQUARE
	CATGUT	VICRYL	TEST
RESIDUAL	PERCENTAGE OF	PERCENTAGE OF	
SUTURES	PATIENTS	PATIENTS	X2 = 13.904
YES	13	0	P = 0.002
			HIGHLY
NO	87	100	SIGNIFICANT



In Group 1, 13 percent of women had remnant suture material at 6 weeks

postpartum, whereas none of the women in Group 2 had any remaining Vicryl.

Because the p value was 0.002, this was statistically significant.

# TABLE : 23 COMPARISION OF INFECTION RATE IN BOTH GROUPSAFTER 6 WEEKS POST PARTUM

FOLLOWUP	6 WEEKS LATER		
			CHI SQUARE
INFECTIO	CATGUT	VICRYL	TEST
N	PERCENTAGE OF	PERCENTAGE OF	
1N	PATIENTS	PATIENTS	X2 = 4.082
YES	4	0	P = 0.0434
			HIGHLY
NO	96	100	SIGNIFICANT



After 6 weeks postpartum, 4% of women in Group 1 reported manifestations of infection, but none in Group 2, with a statistically significant p value of 0.0434.

# TABLE : 24 COMPARISION OF WOUND HEALING 6 WEEKS POSTPARTUM IN STUDY GROUPS

FOLLOWUP 6 WEEKS	LATER		
NATURE OF			
WOUND HEALING	CATGUT	VICRYL	
	PERCENTAGE OF	PERCENTAGE OF	CHI SQUARE
	PATIENTS	PATIENTS	TEST
COMPLETE	90	96	X2 = 2.765
INCOMPLETE	10	4	P = 0.0963



After 6 weeks postpartum, 10% of women in Group 1 and 4% of women in Group 2 had wounds that had not healed completely. When the p value was calculated as 0.0963, it was determined that this was not statistically significant.

## TABLE : 25COMPARISION OF WOUND GAPING 6 WEEKS POSTPARTUM IN STUDY GROUPS

FOLLOWUP 6	WEEKS LATER		
WOUND			
GAPING	CATGUT	VICRYL	
	PERCENTAGE OF	PERCENTAGE OF	CHI SQUARE
	PATIENTS	PATIENTS	TEST
YES	11	5	X2 = 2.446
NO	89	95	P = 11.76



The patients were enquired about wound gaping after 6 weeks postpartum and found that 11% of women in Group 1 had wound gaping to some extent and 5 % in Group 2. This was not statistically significant as p value was 11.76.

#### Method of Statistical Analysis :

In this study the following methods were used to analyse statistical results of the patients in both the groups .

For continuous data , number as well as percentage the results were averaged (mean  $\pm$  standard deviation ) as in cases of variables such as dichotomous data. These are presented in figures and tables.

1) Chi – Square test (  $\chi 2$  ) used for comparison of proportions

Rows	Columns			Total
	1	2	c	
1	<b>a</b> <sub>1</sub>	<b>a</b> <sub>2</sub>	a <sub>c</sub>	<b>t</b> <sub>1</sub>
2	<b>b</b> <sub>1</sub>	<b>b</b> <sub>2</sub>	b <sub>c</sub>	t <sub>2</sub>
•	•		•	•
	•		•	•
r	$h_1$	h <sub>2</sub>	h <sub>c</sub>	t <sub>r</sub>
Total	<b>n</b> <sub>1</sub>	<b>n</b> <sub>2</sub>	n <sub>c</sub>	N

The observed numbers are a, b.....h.

The grand total is denoted as N

$$\boldsymbol{\chi}^{2} = N \left[ \frac{1}{t_{1}} \sum_{1}^{c} \frac{a_{1}^{2}}{n_{i}} + \frac{1}{t_{2}} \sum_{1}^{c} \frac{b_{1}^{2}}{n_{i}} + \dots + \frac{1}{t_{r}} \sum_{1}^{c} \frac{h_{1}^{2}}{n_{i}} - 1 \right]$$

DF=(r-1)\*(c-1), where r means rows and c means columns

DF stands for degrees of freedom (After placing restriction on certain data DF signifies the number of observations that vary freely)

2) Student "T" test
To determine the statistical difference between groups in the parameters that were measured the Students "t" Test was used. It is as follows :

$$t = \frac{\overline{x_1 - x_2}}{s\sqrt{\frac{1}{n_1} + \frac{1}{n_2}}} \sim t_{n_1 + n_2 - 2} \text{ Where } s^2 = \frac{(n_1 - 1)s_1^2 + (n_2 - 1)s_2^2}{(n_1 + n_2 - 2)}$$

To take p value as staistically significant it was said to be less than 0.05. With the help of SPSS package the data in the study were analyzed.

## **DISCUSSION**

Since time immemorial, several research on the use of episiotomy have been conducted, with the result that in cases with tight perineum, limited episiotomy may be more helpful than conventional episiotomy for all persons. <sup>(39)</sup>

First, a comparison between chromic catgut and vicryl, which has been used in the past. Vicryl is less tissue reactive, is absorbed through hydrolysis, and takes longer to absorb, according to the study, resulting in fewer wound infections, faster wound healing, and less postpartum pain. The use of sticky adhesive for episiotomy wounds and studies using the newer substance Dexon are among the most recent.  $^{(40)}$ 

The purpose of this study is to offer quantitative information to help guide suture material selection for episiotomy wound healing following vaginal delivery.

This study is a prospective randomised controlled trial in which 200 individuals were split into two groups and episiotomy suturing techniques and materials were evaluated. The lignocaine local anaesthetic provided adequate pain alleviation. The followups of patients were 24- 48 hours later , on 10th to 14th day and again after 6 weeks postpartum.

As in primgravida, more episiotomies and suturing were necessary, which is in consistent to earlier research on the need for episiotomies, which found that the need for episiotomies was greater in primigravida due to the tight perineum. However, according to the P-value, the difference is not significant.

In terms of age, parity, BMI, gestational age, gravidity status and the demographic data revealed no differences. There was no statistically significant difference between the two groups when it came to perineal tears, type of analgesic used and birth weight, all of which are significant prognostic indicators.

Pain was the most studied cumulative measure, with statistically significant differences in pain across procedures and suture materials. As in group 1, those who had catgut had the suture material, and the mucosa closure was continuous interlocking, followed by a muscle layer with intermittent layer, and finally a mattress suture at the skin level. When vicryl was utilised in group 2, the skin layer was closed with continuous buried subcutaneous sutures, but the remainder of the technique remained the same.

The vicryl rapid continuous group had significantly lower pain perception than the catgut group after 24 to 48 hours postpartum, and the same pattern was observed at 10 to 14 days and 6 weeks followups, where the majority of women in both groups had no pain at all, and the majority of those who did had pain belonged to the catgut group. This was statistically significant, as evidenced by the use of a more objective VAS scale at each follow-up, as well as the number of analgesics used. When asked about painful or tight sutures at the perineal region, women in Group 1 reported higher discomfort than women in Group 2 24 to 48 hours after delivery and 10 to 14 days later, which was statistically significant.

Masson et al. evaluated pain in 2000 patients throughout the postnatal period and discovered a significant difference in pain in the polyglactin group, with considerably reduced discomfort.<sup>(41)</sup>

On postnatal day 2, the polyglactin group reported 51 percent pain compared to 61 percent in the catgut group, according to Shah PK's research.<sup>(42)</sup>

In an Ipswich birthing study comparing two suture materials, the polyglactin group showed a definite advantage of reduced pain at 48 hours postpartum.<sup>(10)</sup>

The patients were followed for three months following birth in these studies, and dyspareunia was compared between the two groups. There were no statistically significant differences between the two groups, according to the research.

Kettle C and Johanson RB conducted a Cochrane systematic review of eight randomised controlled trials including 3642 women and found no discernible difference in long-term pain and dyspareunia between the absorbable synthetic and catgut suture materials. <sup>(8)</sup> Mackrodt C et al and Shah PK et al found no significant differences between the two groups. <sup>(10)</sup>

Moving on to additional comparison criteria such as infection, none of the women had any symptoms or indications of infection after 24 - 48 hours or after 10 - 14 days postpartum, while 4% of women in the catgut group had a minor infection that required outpatient treatment after 6 weeks. Because the p value was 0.0434, this was statistically significant. This was another another positive element in the vicryl group's favour.

At each follow-up postpartum, the women were asked about wound gaping. More women experienced gaping in the I catgut group (7 percent over 3 percent after 24 to 48 hours, 14 percent over 4 percent after 10 - 14 days, and 11 percent over 5 percent after 6 weeks postpartum), but only after 10 - 14 days postpartum was it statistically significant. None of them, however, needed re-suturing of the gap. This was, however, another element that favoured the Vicryl group.

Though this data may not be theoretically or statistically significant, we observed wound dehiscence in solely the catgut intermittent group, which

is commonly used in government hospitals and may be replaced with better options.

In the Ipswich Childbirth study, the appearance of wound gaping did not differ between the two groups after 24-48 hours. <sup>(10)</sup> At 6 to 8 weeks, other studies (Greenberg et al, Leroux et al, Kurian et al) found no difference in wound healing. <sup>(11,12,13)</sup>

After 6 weeks, 13% of the women in the catgut group had residual sutures at the wound site, but none of the women in the vicryl group did. Because the p value was 0.002, this was statistically significant. Overall, 10% of the women in the catgut group had incomplete wounds at 6 weeks postpartum, whereas only 4% of the women in the vicryl group had incomplete wounds.

According to a study conducted in Davangare, the primary goal of wound healing was obvious in 82 percent of cases in the vicryl rapide group and 71 percent of cases in the chromic catgut group. The tertiary type was detected in 2% of cases in the chromic catgut group, but not in the vicryl rapide group.

A 2017 research at Dharmapuri Medical College compared catgut to absorbable synthetic suture material and found that the polyglactin group had superior wound healing with nil or zero percent wound dehiscence on PND 7, compared to 15% in the catgut group, which is consistent with our findings.<sup>(43)</sup>

The continuous procedure was found to be superior to the intermittent technique in a study conducted in Maharashtra comparing two methods of suturing and wound repair in India's rural population, with 58 percent of

75

the continuous suturing group experiencing discomfort versus 76 % of the intermittent group having pain. <sup>(44)</sup>

These findings are in accordance with previous research, which has indicated that vicryl rapide heals wounds faster than chromic catgut. Previous study has indicated that intermittent suturing is less successful than continuous suturing and that monofilament polyglactin is a superior wound healing alternative than chromic suturing.

## **SUMMARY**

In Shri BM Patil Medical College, we conducted a randomised prospective study on 200 women who required an episiotomy incision during labour after a normal vaginal delivery. They were split into two groups of 100, one for Catgut and the other for Vicryl.

The two groups were matched in terms of age, gestational age, BMI, labour time, use of labour analgesia, and birth weight.

They were all assessed after delivery at 24-48 hours, 10-14 days, and 6-8 weeks.

The patients were then observed for pain at the wound site, the severity of the discomfort, and whether or not analgesics were needed, edema, temperature or local warmth, induration, wound healing-discharge, and dehiscence over the postnatal period.

On comparing the wound healing nature of both groups, similar findings were obtained at 24 to 48 hours and 10 to 14 days postpartum, but the vicryl group fared better in terms of residual suture material, wound gap, and wound site infection, especially towards the end of 6 weeks postpartum.

At 24 to 48 hours, 10 to 14 days, and 6 weeks postpartum, more women in the catgut group had pain and discomfort than those in the vicryl group, and more so in the severe category on the VAS scale.

# **CONCLUSION**

Evidently, absorbable sutures should be utilised during episiotomy. Because polyglycolic sutures are non-allergenic, have a higher tensile strength, are less prone to cause discomfort, and are less likely to cause infection, they are preferred over chromic catgut sutures. Although catgut is an option, it is not the best suture material.

Suturing with a continuous approach is better than intermittent suturing seeing as it reduces the time, uses fewer material, involves minimal knots, and therefore causes less pain.

# **BIBLIOGRAPHY**

- 1. William s obstetrics 25 th edition pg 782
- Kalis V, Landsmanova J, Bednarova B, et al: Evaluation of the incision angle of mediolateral episiotomy at 60 degrees. Int J Gynaecol Obstet 112:220, 2011
- Reproduced with permission from Kenton K, Mueller M: Episiotomy and obstetric anal sphincter lacerations. In Yeomans ER, Homan BL, Gilstrap LC III, et al (eds): Cunningham and Gilstrap's Operative Obstetrics, 3rd ed. New York, McGraw-Hill Education, 2017.)
- 4. Kargar R, Aghazadeh-Nainie A, Khoddami-Vishteh HR: Comparison of the e78ects of lidocaine prilocaine cream (EMLA) and lidocaine injection on reduction of perineal pain during perineum repair in normal vaginal delivery. J Family Reprod Health 10(1):21, 2016
- 5. de Leeuw JW, Struijk PC, Vierhout ME, et al: Risk factors for third degree perineal ruptures during delivery. BJOG 108(4):383, 2001
- Fodstad K, Laine K, Sta78 AC: Di78erent episiotomy techniques, postpartum perineal pain, and blood loss: an observational study. Int Urogynecol J 24(5):865, 2013
- Karbanova J, Rusavy Z, Betincova L, et al: Clinical evaluation of early postpartum pain and healing outcomes a78er mediolateral versus lateral episiotomy. Int J Gynaecol Obstet 127(2):152, 2014a
- Kettle C, Hills R K Jones P, Darby L, Gray R, Johanson R, 2002, Continuous versus interrupted perineal repair with standard or rapidly absorbed sutures after spontaneous vaginal birth: a randomized controlled trial, Lancet, 359, 2217-2223
- Kettle C, Dowswell T, Ismail KMK, 2010, Absorbable synthetic versus catgut suture material for perineal repair (Cochrane Review), In: The Cochrane Library, Issue 6.

- 10.Mackrodt C, Gordon B, Fern E Ayers S, Truesdale A, Grant A, 1998, The Ipswich Childbirth Study: 2. A randomized comparison of polyglactin 910 with chromic catgut for postpartum perineal repair, Br J ObstetGynaecol, 105, 441-445.
- 11.Greenberg JA, Lieberman E, Cohen AP, Ecker JL, 2004, Randomized comparison of Chromic Versus Polyglactin 910 for Postpartum Perineal Repair, Am J ObstetGynecol, 103, 6, 1308-1313.
- 12.Leroux N, Bujold E, 2006, Impact of Chromic Catgut versus Polyglactin 910 versus fast-absorbing polyglactin 910 sutures for perineal repair: A randomized controlled trial, Am J ObstetGynecol, 194, 6, 1585-1590.
- 13.Kurian Bhaskaran S, Prakash S, 2008, Comparative study of episiotomy repair: absorbable synthetic versus chromic catgut suture material, J ObstetGynecol India, 58, 6, 495-499.
- 14.Snell Richard S. The perineum. 6<sup>th</sup> ed. Chapter 8. In: Clinical Anatomy for medical students. Lippincott Williams and Wilkins; 2000. p. 355.
- 15.Wooley R. Benefits and risks of episiotomy: A review of the English language literature since 1980 I and II. Obstet Gynecol Surv 1995;50:806-35.
- 16.Graham I. Nineteenth century challenging of the emergency use of episiotomy. In: Episiotomy: Challenging obstetric investigations. London: Blackwell Scientific; 1997. pp. 50-2.
- 17.Robinson JN, Norwitz ER, Cohen AP, Lieberman E. Predictors of episiotomy use at first spontaneous vaginal delivery. Obstetrics & Gynecology. 2000 Aug 1;96(2):214-8.
- 18.Myers-Helfgott MG, Helfgott AW. Routine use of episiotomy in modern obstetrics: Should it be performed?. Obstetrics and gynecology clinics of North America. 1999 Jun 1;26(2):305-25.

- 19.Amorim MM, Coutinho IC, Melo I, Katz L. Selective episiotomy vs. implementation of a non-episiotomy protocol: a randomized clinical trial. Reproductive health. 2017 Dec;14(1):1-0.
- 20.Rockner G, Jonasson A, Olund A, 1991, The effect of mediolateral episiotomy at delivery on pelvic floor muscle strength evaluated with vaginal cones. Acta Obstet Gynecol Scand, 70: 51-54.
- 21.American College of Obstetrics and Gynecology : April 2006 Episiotomy Practice Bulliten No. 71.
- 22.Royal College of Obstetrics and Gynecology : Methods and Materials used in perineal repair 2004 guidelines; No. 23, London (U.K): Royal College of Obstetrics and Gynecology.
- 23.Sagi-Dain L, Sagi S. Indications for episiotomy performance–a crosssectional survey and review of the literature. Journal of Obstetrics and Gynaecology. 2016 Apr 2;36(3):361-5.
- 24.Rusavy Z, Karbanova J, Kalis V. Timing of episiotomy and outcome of a non-instrumental vaginal delivery. Acta obstetricia et gynecologica Scandinavica. 2016 Feb;95(2):190-6.
- 25.Kalis V, Laine K, De Leeuw JW, Ismail KM, Tincello DG. Classification of episiotomy: towards a standardisation of terminology. BJOG: an international journal of obstetrics & gynaecology. 2012 Apr;119(5):522-6.
- 26. Verspyck E, Sentilhes L, Roman H, Sergent F, Marpeau L. Episiotomy techniques. Journal de gynecologie, obstetrique et biologie de la reproduction. 2006 Feb 1;35(1 Suppl):1S40-51.
- 27. Doumouchtsis, S., 2018. Childbirth Trauma.
- 28.Hale, R. and Ling, F., 2007. Episiotomy. Washington, D.C.: American College of Obstetricians and Gynecologists.
- 29.Mohamed HA, El-Nagger NS. Effect of self perineal care instructions on episiotomy pain and wound healing of postpartum women. Journal of American Science. 2012;8(6):640-50.

- 30.Sheikhan F, Jahdi F, Khoei EM, Shamsalizadeh N, Sheikhan M, Haghani H. Episiotomy pain relief: Use of Lavender oil essence in primiparous Iranian women. Complementary therapies in clinical practice. 2012 Feb 1;18(1):66-70.
- 31.Eskandar O, Shet D. Risk factors for 3rd and 4th degree perineal tear. Journal of Obstetrics and Gynaecology. 2009 Jan 1;29(2):119-22.
- 32.Gün İ, Doğan B, Özdamar Ö. Long-and short-term complications of episiotomy. Turkish journal of obstetrics and gynecology. 2016 Sep;13(3):144.
- 33.George Broughton II, Janis JE, Attinger CE. Wound healing: an overview. Plastic and reconstructive surgery. 2006 Jun 1;117(7S):1e-S.
- 34.Phillips SJ. Physiology of wound healing and surgical wound care. ASAIO journal. 2000 Nov 1;46(6):S2-5.
- 35.Chu CC. Classification and general characteristics of suture materials. InWound Closure Biomaterials and Devices 2018 May 4 (pp. 39-63). CRC Press.
- 36.Shaieb MD, Singer DI. Tensile strengths of various suture techniques. Journal of Hand Surgery. 1997 Dec;22(6):764-7.
- 37.Sajid MS, McFall MR, Whitehouse PA, Sains PS. Systematic review of absorbable vs non-absorbable sutures used for the closure of surgical incisions. World journal of gastrointestinal surgery. 2014 Dec 27;6(12):241.
- 38.Kokanalı D, Ugur M, Kokanalı MK, Karayalcın R, Tonguc E. Continuous versus interrupted episiotomy repair with monofilament or multifilament absorbed suture materials: a randomised controlled trial. Archives of gynecology and obstetrics. 2011 Aug;284(2):275-80.
- 39.Bruce E. Get Through Childbirth in One Piece!: How to Prevent Episiotomies and Tearing. iUniverse; 2001.

- 40.Bharathi A, Reddy DD, Kote GS. A prospective randomized comparative study of vicryl rapide versus chromic catgut for episiotomy repair. Journal of clinical and diagnostic research: JCDR. 2013 Feb;7(2):326.
- 41.Joseph K, Shantha B, Prakash S. Comparative study of episiotomy repair: Absorbable synthetic versus chromic catgut suture material. JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA. 2008 Nov 1;58(6):495-9.
- 42.Kalita R. To Compare the Clinical Outcomes Following Episiotomy Wound Repair Using Chromic Catgut versus Fast Absorbing Polyglactin 910. Sch J App Med Sci. 2021 Jun;6:1056-61.
- 43.Aiswarya R. A comparitive study of episiotomy suturing-chromic catgut vs vicryl rapide and continuous vs intermittent suturing: A randomised controlled study (Doctoral dissertation, Government Mohan Kumaramangalam Medical College, Salem).
- 44.Bahulekar A, Vaswani B, Patange R. Continuous versus interrupted sutures for episiotomy wound repair. Journal of Evolution of Medical and Dental Sciences. 2016 Nov 28;5(95):7016-9.
- 45.Abdullah M, Noreen A, Iqbal M, Sohail R. COMPARISON BETWEEN CHROMIC CATGUT AND VICRYL RAPIDE FOR ANALGESIA REQUIREMENT IN EPISIOTOMY REPAIR IN PRIMIGRAVIDAS. 2015;21(3):193–6
- 46.Sleep J, Grant A, Garcia J, Elbourne D, Spencer J, Chalmers I. West Berkshire perineal management trial. Br Med J (Clin Res Ed). 1984 Sep;289(6445):587–90.
- 47.Sartore A, De Seta F, Maso G, Pregazzi R, Grimaldi E, Guaschino S. The Effects of Mediolateral Episiotomy on Pelvic Floor Function After Vaginal Delivery. Obstet Gynecol. 2004 Apr;103(4):669–73.

- 48.Mandade K, DP B. Comparative Study of Continuous Vs. Intermittent Technique of Episiotomy Suturing in Rural Population of India. Int J Med Sci Clin Invent. 2016;3(10):2281–4.
- 49.Bahulekar A, Vaswani B, Patange R. Continuous Versus Interrupted Sutures for Episiotomy Wound Repair. J Evol Med Dent Sci. 2016;5(95):7016–8.
- 50.Mota R, Costa F, Amaral A, Oliveira F, Santos CC, Ayres-De-Campos D. Skin adhesive versus subcuticular suture for perineal skin repair after episiotomy – a randomized controlled trial. Acta Obstet Gynecol Scand. 2009 Jan;88(6):660–6.
- 51.Fernando RJ, Sultan AH, Kettle C, Thakar R. Methods of repair for obstetric anal sphincter injury. In: Fernando RJ, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2013. p. CD002866.
- 52.Jena L, Kanungo S. Acomparative study of continuous versus interrupted suturing for repair of episiotomy or second degree perineal tear.Int J ReprodContracept Int J ReprodContracept Obs Gynecol. 2015;44(1):52–5.
- 53.Bahulekar A, Vaswani B, Patange R. CONTINUOUS VERSUS INTERRUPTED SUTURES FOR EPISIOTOMY WOUND REPAIR. J Evol Med Dent Sci. 2016;5(95).
- 54.Perumal D, Selvaraju D. Comparative study of episiotomy repair: absorbable synthetic versus chromic catgut suture material. Int J Reprod Contraception, Obstet Gynecol. 2017 May;6(6):2186.
- 55.Gemynthe A, Langhoff-Roos J, Sahl S, Knudsen J. New VICRYL\* formulation: an improved method of perineal repair? Br J Midwifery. 1996 May;4(5):230–4.
- 56.Gulab Nagure A, Chacko V, Darakshan Saleem MM. Continuous vs interrupted sutures for the repair of episiotomy: A comparative study. Indian J Basic Appl Med Res. 2013;(2).

### ANNEXURES

## ETHICAL CLEARANCE CERTIFICATE



IEC/NO-131/2019 22-11-2019

B.L.D.E. (DEEMED TO BE UNIVERSITY) (Declared vide notification No. F.9-37/2007-U.3 (A) Dated. 29-2-2008 of the MHRD, Government of India under Section 3 of the UGC Act, 1956) The Constituent College SHRI. B. M. PATIL MEDICAL COLLEGE, HOSPITAL AND RESEARCH CENTRE

### INSTITUTIONAL ETHICAL CLEARANCE CERTIFICATE

The ethical committee of this college met on 13-11-2019 at 3-15 pm to scrutinize the synopsis of Postgraduate students of this college from Ethical Clearance point of view. After scrutiny the following original/corrected and revised version synopsis of the Thesis has been accorded Ethical Clearance

Title: Fast-absorbing polyglactin 910 versus chromic catgut suture for repair of episiotomy: a randomized comparative study

Name of PG student: : Dr. Jada Susmitha, Department of OBG

Name of Guide/Co-investigator: Dr (Mrs) Shailaja. R. Bidri, Professor Department of OBG

DR RAGHVENDŘA KULKARNI CHAIRMAN Institutional Ethical Committee BLDEU's Shri B.M. Patil Medical Collego,BIJAPUR-586103

Following documents were placed before Ethical Committee for Scrutinization:

1. Copy of Synopsis / Research project

2. Copy of informed consent form

3. Any other relevant documents.

46

# INFORMED CONSENT FOR PARTICIPATION IN DISSERTATION/RESEARCH

I, the undersigned, \_\_\_\_\_, D/O W/O \_\_\_\_\_, aged \_\_\_\_years, ordinarily resident of \_\_\_\_\_\_ do hereby state/declare that Dr JADA SUSMITHA of Shri. B. M. Patil Medical College Hospital and Research Centre has examined me thoroughly on \_\_\_\_\_\_ at \_\_\_\_\_ (place) and it has been explained to me in my own language that I am suffering from disease (condition) and this disease/condition mimic following diseases. Further Dr JADA SUSMITHA informed me that he/she is conducting dissertation/research titled "Fast-Absorbing Polyglactin 910 versus Chromic Catgut suture for Repair of Episiotomy: A Randomized Comparative Study" under the guidance of Dr.SHAILJA R BIDRI requesting my participation in the study. Apart from routine treatment procedure, the pre-operative, operative, post-operative and follow-up observations will be utilized for the study as reference data. Doctor has also informed me that during conduct of this procedure like adverse results may be encountered. Among the above complications most of them are treatable but are not anticipated hence there is chance of aggravation of my condition and in rare circumstances it may prove fatal in spite of anticipated diagnosis and best treatment made available. Further Doctor has informed me that my participation in this study would help in evaluation of the results of the study which is useful reference to treatment of other similar cases in near future, and also I may be benefited in getting relieved of suffering or cure of the disease I am suffering.

The Doctor has also informed me that information given by me, observations made photographs video graphs taken upon me by the investigator will be kept secret and not assessed by the person other than me or my legal hirer except for academic purposes. The Doctor did inform me that though my participation is purely voluntary, based on information given by me, I can ask any clarification during the course of treatment / study related to diagnosis, procedure of treatment, result of treatment or prognosis. At the same time I have been informed that I can withdraw from my participation in this study at any time if I want or the investigator can terminate me from the study at any time from the study but not the procedure of treatment and follow-up unless I request to be discharged. After understanding the nature of dissertation or research, diagnosis made, mode of treatment, I the undersigned Smt \_\_\_\_\_\_ under my full conscious state of mind agree to participate in the said research/dissertation.

Signature of patient:

Signature of doctor:

Date:

Place

# PROFORMA

## <u>Fast</u> -Absorbing Polyglactin 910 versus Chromic Catgut suture for Repair of Episiotomy: A Randomized Comparative Study

NAME:

AGE:

IN PATIENT NUMBER (I.P No.):

DATE OF ADMISSION :

ADDRESS AND PHONE NUMBER :

L.M.P ( LAST MENSTRUAL PERIOD ) :

P.O.G (PERIOD OF GESTATION):

E.D.D ( EXPECTED DATE OF DELIVERY ):

MENSTRUAL HISTORY :

MARITAL HISTORY (INCLUDING HISTORY OF DYSPAREUNIA):

**OBSTETRIC HISTORY:** 

FIRST TRIMESTER:

SECOND TRIMESTER:

THIRD TRIMESTER:

PAST HISTORY:

PERSONAL HISTORY:

GENERAL PHYSICAL EXAMINATION:

HEIGHT: WEIGHT:

PALLOR:

TEMPERATURE: PULSE:

BLOOD PRESSURE:

CARDIOVASCULAR SYSTEM:

**RESPIRATORY SYSTEM:** 

PER ABDOMEN:

PRESENTATION:

**INVESTIGATIONS:** 

ULTRASOUND REPORT:

MODE OF DELIVERY:

PER VAGINAL:

**BIRTH WEIGHT:** 

DATE OF DELIVERY:

LABOUR ANALGESIA:

DURATION OF STAGES OF LABOUR:

EPISIOTOMY: YES / NO SUTURE MATERIAL: CC / FAP

METHOD OF PERINEAL REPAIR: PERINEAL TEARS:

ANALGESIA PRESCRIBED AFTER DELIVERY:



NUMERIC PAIN INTENSITY SCALE

## OUTCOME AT 24-48 HRS

- 1. Time since delivery (Hrs)
- 2. Perineal pain during past 24 hrs : no/mild/moderate/severe
- 3. Number of doses of analgesia used during past 24 hrs :
- 4. Tight/uncomfortable sutures : yes / no
- 5. Infection at episiotomy site:
- 6. Appearance of perineal gaping :

### OUTCOME AT 10-14 DAYS

- 1. Time since delivery ( days ) :
- 2. Residual perineal pain :
- 3. Analgesia required in past 24 hrs :
- 4. Tight/uncomfortable sutures : yes /no
- 5. Need for suture removal
- 6. Nature of wound healing :
- 7. Need for resuturing :
- 8. Need for in-patient treatment :

### OUTCOME AT 6 – 8 WEEKS

- 1. Time since delivery (weeks):
- 2. Residual perineal pain : yes/no
- 3. Analgesic required during past 1 week for perineal pain : yes/no
- 4. Residual suture material : yes/no
- 5. Nature of wound healing :
- 6. Need for inpatient treatment :

	Name	IP NO	Ag (Y)	e Bi rs)(K	MI (G/	POG (wee	Gestation	POG	OB S	GRA I	PAL RAII	N A	DE AB	O Su O ur	t PEF P INE	TAK	NO N OF	BIRT	SIC	E 24 TO	Perinea I Pain	Pe	No Of	Tight/ Uncom	Infe	Gapin 10	Residua I Pain	Resi dual	Nee d for	Tight /Unc	Infe ctio	Nature of Wound	6 Wee	dual	Nee d	dua	ctio W	ature of Jound	Gaping
				N	12)	ks)			SC A	A	G	3	N	M	AL	то	SU	WE	G USED	48		eal Pai	Dos	fortabl	n	14		Pain	Anal	omf	n	Healing	ks late	Pain	for	l Sut	n He	ealing	
1	SAVITA JOLAD	40754	25	2	2	39	4	39.6		2	0 0	0	1	CC	NO	20.0	1.0	3.0	lbuprofe	n	Mild	3	3	Yes	No	No	No	0	No	No	No	Satisfactory	lace	No	No	No	No Co	omplete	no
2	MAHANANDA	40844	27	2	1	39	0	39		2	1 1	L O	0	cc	NO	25.0	0 1.0	0 2.86	ibuprofe	n	Modera	5	3	Yes	No	No	Mild	1	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
3	MATH DEEPA BABE	42636	26	1	9	39	6	39.9		2			0		NO	19.0	0 1 0	0 2 76	diclo		te Mild	2	3	No	No	No	Mild	1	No	No	No	Satisfactory		No	No	No	No. Cr	omplete	00
		12010		-		40	-	40.2					-			25.0			thunsofa			-		Mar				-		Mar		Coll de terre							
•	ANITA DALAVAL	43049	20	2	2	40	2	40.3				, ,			NU	25.0	2.0	2.7	auprore		te	0	4	res	NO	IND	NO	0	NO	tes	NO	Satisfactory		NO	NO	NO	NO CO	ompiece	no
5	DANAKKA PUJARI	43289	21	1	5	37	3	37.4		2	1 1	. 0	0	co	NO	20.0	0 1.0	0 2.20	buprofe	n	Modera te	5	4	Yes	No	No	Mild	2	No	Yes	No	Superficial Gaping		No	No	No	No In e	complet	yes
6	GEETA HARIZAN	43348	22	1	8	38	2	38.3		2	1 1	LO	0	cc	NO	30.0	0 2.0	0 3.24	buprofe	n	Modera te	4	3	Yes	No	No	Mild	2	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
7	SHREEDEVI BADIGERI	43353	27	1	9	39	1	39.1		1	0 0	0	0	cc	NO	25.0	0 1.5	0 2.10	diclo		Mild	2	3	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
8	MEENAZ SANAVAD	43520	20	1	9	40	3	40.4		1	0 0	0	0	С	NO	20.0	0 1.5	0 3.12	Ibuprofe	n	Modera	6	4	No	No	No	Modera	4	No	No	No	Superficial		No	No	No	No Co	omplete	no
9	SHRUTI	44567	23	2	0	36	4	36.6		1	0 0	0	0	С	NO	24.0	0 1.0	0 2.60	buprofe	n	Modera	6	3	Yes	No	No	Modera	4	No	Yes	No	Satisfactory		No	No	No	No Co	omplete	no
10	BHAGAMMA	43776	20	1	7	39	1	39.1		1	0 0	0 0	0	cc	YES	26.0	0 1.0	0 2.90	diclo		te Severe	8	4	Yes	No	Super	te Severe	7	Yes	Yes	No	Superficial		yes	yes	yes	yes In	complet	yes
11	POOJA	340	25	1	8	38	6	38.9		2	1 1	1 0	0	cc	NO	21.0	0 2.0	0 2.90	buprofe	n	Mild	3	3	Yes	No	ficial	No	0	No	No	No	Gaping Satisfactory		No	No	No	e No Co	omplete	no
12		600	25	2	0	40	2	40.4					-		NO	16.0	0 1 5	0 2 20	Bunrofe	n	Madara	6	4	Vor	No	No	Mild	2	No	No	No	Satisfactory		No	No	No	No. Co	omplete	
12	LAAMIPATIL	600	25	2	•	40	3	40.4				, ,			NU	10.0	0 1.5	0 3.20	, aspiole		te	0	*	165	NO	NO	MIIG	2	NO	NO	NO	Satisfactory		NO	NO	NO	NO CO	ompiete	no
13	KANYAKUMARI	764	22	21	0	39	5	39.7		3	2 1	1 1	0	cc	NO	13.0	0 1.0	0 2.50	buprofe	n	Mild	2	3	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
14	ASHWINI	945	24	2	4	39	2	39.3		3	1 1	L O	1	co	NO	20.0	0 2.0	0 2.60	buprofe	n	Modera te	5	3	No	No	No	Modera te	4	No	No	No	Superficial Gaping		yes	yes	yes	yes Co	omplete	yes
15	GAYATRI SUTAR	979	32	2	2	41	4	41.6		3	2 2	2 0	0	co	NO	27.0	0 1.5	0 2.90	buprofe	n	Modera	4	3	No	No	No	Modera	5	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
16	SANGEETA SULL	999	20	2	0	40	4	40.6		1	0 0	0	0	СС	NO	25.0	0 1.0	0 2.20	buprofe	n	Modera	6	3	No	No	No	Mild	3	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
17	SAVITA LAMANI	1157	31	1	8	39	4	39.6		3	2 2	2 0	0	С	NO	16.0	0 1.0	0 1.50	) Ibuprofe	n	te Mild	2	3	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
18	SHIRKANYA	1409	24	1	8	36	6	36.9		1	0 0	) 0	0	cc	NO	22.0	0 1.0	0 2.30	buprofe	n	Modera	6	3	Yes	No	No	Mild	4	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
10	SHARANBASAPA	1502	22	1	7	40	2	40.4				2 0			NO	26.0	0.20	0 2 66	Bunrofe	0	te	0	4	Vor	No	Super	Smioro	7	Vor	Vor	Vor	Superficial		WAF	LINE	une	war In	complet	1000
	NORSANA	1555	~	-	<u> </u>			40.4		, .						20.0	0 2.0	0 3.00			Jevere	,			NU	ficial	Jevere	Ĺ	les	ies	res	Gaping		yes	yes	yes	e	compret	yes
20	SUNITA MASALI	1794	24	1	9	40	4	40.6		3	2 1	1	. 0	cc	NO	23.0	0 1.5	0 3.44	buprote	n	Mild	2	3	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
21	GEETA JADHAV	2033	21	2	4	38	1	38.1		3	1 1	L O	1	co	NO	14.0	0 1.0	0 2.80	buprofe	n	Modera te	5	3	Yes	No	No	Modera te	4	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
22	SAMEENA MALASAI	2114	20	2	3	36	3	36.4		1	0 0	0	0	cc	NO	28.0	0 1.5	0 2.70	diclo		Severe	7	3	Yes	No	No	Severe	8	Yes	Yes	No	Satisfactory		No	No	No	No Co	omplete	no
23	ARUNA PUJAR	1984	24	2	0	37	6	37.9		6	1 1	L O	2	co	NO	19.0	0 2.0	0 3.61	Ibuprofe	n	Mild	1	3	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
24	LAXMI KUMBA	4337	22	2	1	38	6	38.9		2	1 1	L 0	0	С	NO	17.0	0 1.0	0 2.98	Ibuprofe	n	Modera	6	3	Yes	No	Super	Severe	7	Yes	No	No	Superficial		No	No	No	No Co	omplete	no
25	ANAJANA	4588	20	1	9	39	4	39.6		1	0 0	0 0	0	cc	NO	16.0	0 1.5	0 2.50	diclo		te Modera	5	3	No	No	ficial No	Modera	5	No	No	No	Gaping Satisfactory		No	No	No	No Co	omplete	no
26	SUJATA	4333	21	1	8	39	6	39.9		1	0 0	) 0	0	cc	NO	15.0	0 1.0	0 2.60	buprofe	n	te Mild	3	4	No	No	No	te Modera	5	No	No	No	Satisfactory		No	No	No	No Co	omplete	00
27	NACADNA	FOCA				20		20.0					-			15.0	0.20	0.00	- Ibuorofa		Madam	-		Mag	No	funner.	te		Ver	No	No	funeficial							
27	NAGARINA	2204	20	1	•	39	0	39.9			5 0	, ,			NU	15.0	0 2.0	0 3.00	, interiore		te	0	3	165	NO	ficial	Severe	0	res	NO	NO	Gaping		yes	yes	yes	yes in e	complet	yes
28	BHAGYASHREE	5753	24	21	0	40	0	40		2	0 0	0	1	co	NO	20.0	0 1.0	0 2.76	Ibuprofe	n	Severe	8	3	Yes	No	No	Modera te	4	Yes	Yes	No	Satisfactory		No	No	No	No Co	omplete	no
29	PAVITRA BIDARI	6625	28	2	1	37	1	37.1		1	0 0	0	0	co	NO	17.0	0 1.5	0 2.70	buprofe	n	Mild	3	4	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
30	RAJASHREE	6832	28	2	7	38	2	38.3		1	0 0	0	0	cc	NO	10.0	0 1.5	0 3.10	Ibuprofe	n	Modera te	5	4	Yes	No	No	Mild	2	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
31	SHOBHA	6519	27	2	1	39	0	39		2	1 1	L O	0	co	NO	20.0	0 2.0	0 3.80	buprofe	n	Mild	2	3	Yes	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
32	MALAMA	6571	22	2	0	41	0	41		1	0 0	0	0	С	NO	15.0	0 1.5	0 3.00	buprofe	n	Modera	4	3	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
33	SALEEMA	6182	22	1	7	38	1	38.1		2	1 1	L 0	0	cc	NO	16.0	0 1.5	0 2.30	buprofe	n	te Modera	4	3	Yes	No	No	Mild	3	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
34	ANNAPURA	4499	35	1	4	37	2	37.3		1	0 0	) 0	0	cc	NO	22.0	0 1.5	0 2.50	buprofe	n	te Severe	7	3	Yes	No	Super	Severe	7	Yes	Yes	No	Satisfactory		No	No	No	No Co	omplete	00
25				-		20	-	20.0					-			20.0	0.20	0.040	Bunnafa		a citat		-	No	N.	ficial	Madam					Callefratery							
35	LAAIMI	4141		-	•	39	0	39.9		2	5 0	, ,	1		NU	20.0	0 2.0	0 3.40	is aprove		Mild	2	3	NO	NO	IND	te	<i>′</i>	NO	NO	NO	Satisfactory		NO	NO	NO	NO CO	ompiece	no
36	JAYASHREE	6890	24	1	8	41	3	41.4		1	0 0	0	0	co	NO	30.0	0 1.5	0 2.58	Ibuprofe	n	Modera te	6	3	Yes	No	No	Mild	3	No	Yes	No	Satisfactory		No	No	No	No Co	omplete	no
37	AMRITA	3966	21	1	5	38	6	38.9		1	0 0	0	0	cc	NO	10.0	0 1.5	0 2.82	diclo		Modera te	7	3	Yes	No	No	Modera te	5	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
38	SUJATHA	5277	19	2	1	39	6	39.9		2	0 0	0	1	co	NO	20.0	0 1.0	0 2.40	diclo		Mild	2	3	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
39	LAXMI	5572	25	1	6	37	3	37.4	:	1	0 0	0	0	СС	YES	15.0	0 1.0	0 2.50	diclo	-	Modera	7	4	Yes	No	Super	Modera	4	Yes	No	No	Superficial	-	yes	No	yes	No in	complet	yes
40	DURGADEVI	4876	30	1	4	39	4	39.6		2	1 1	L 0	0	cc	NO	18.0	0 2.0	0 3.06	i Ibuprofe	n	te Modera	7	4	No	No	ficial No	te Modera	4	No	No	No	Gaping Satisfactory		No	No	No	e No Co	omplete	no
41	BASAMMA	8197	25	1	8	38	2	38.3		2	1 1	LO	0	cc	NO	21.0	0 1.0	0 2.15	Ibuprofe	n	te Mild	2	4	No	No	No	te No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
42	LAYNE	7473	20	2	0	40		40.7							NO	16.0	0.15	0 2 50	hunrofe		Madara	7		Ver	No	No	Madara		No	No	No	Enticfactory		No	No	No	No. Cr	amplate	
42	DAIRA	8105	20	-	-	20	- -	20.7								10.0	- 1.5	0 2.36			te			Ve-		Ne	te	-				Ention		AU			No C	- inprece	
43	KAJEMA	8106	25	2	1	38	U	38		٤	1	. 0	0	co	NO	18.0	U 2.0	U 3.20	diclo		Severe	8	4	fes	No	NO	Severe	7	No	Yes	No	satisfactory		No	No	No	NO CO	omplete	no
44	SRUTI	8130	24	1	5	38	6	38.9		1	0 0	0	0	co	NO	27.0	0 1.0	0 3.10	Ibuprofe	n	Mild	2	3	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
45	REKHA	7895	25	1	4	38	5	38.7		2	1 1	L 0	0	co	NO	14.0	0 1.5	0 3.20	Ibuprofe	n	Modera te	6	3	Yes	No	No	Mild	2	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
46	VAISHALI	7833	24	1	6	42	0	42		1	0 0	0	0	cc	NO	15.0	0 2.0	0 3.44	lbuprofe	n	Severe	8	3	Yes	No	No	Modera	4	No	Yes	No	Satisfactory		No	No	No	No Co	omplete	no
47	JYOTI	7645	21	2	2	41	0	41		2	0 0	0	1	СС	NO	18.0	0 2.0	0 3.00	buprofe	n	Mild	2	4	No	No	No	No	0	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
48	SULEKADEVI	7884	37	2	4	37	0	37		2	0 0	0	1	cc	NO	22.0	0 1.0	0 2.50	buprofe	n	Modera	5	4	Yes	No	No	Modera	5	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
49	RENNUKA	8847	35	2	0	40	0	40		2	0 0	0	1	cc	NO	14.0	0 1.0	0 2.50	) Ibuprofe	n	te Severe	7	4	Yes	No	Super	te Severe	7	Yes	Yes	No	Satisfactory		No	No	No	No Co	omplete	no
50	GAVATRI SUTAR	8720	20	2		26	4	26.6							NO	21.0	0 1 0	0 2 70	diclo		Mild	2	2	No	No	ficial	No	0	No	No	No	Satisfactory		No	No	No	No. Cr	omplete	
	SATATRI SUTAR	0750	20	2	-	30	4	30.0				. 0				21.0	0 1.0	o 2.7L			Dimen	-	2		110			Č,	nid .	niù	140	Calification			A10	nið N		suprece	10
51	NIRMALA	8206	22	2	2	39	6	39.9		1	υ 0	0	0	co	NO	27.0	υ 1.5	U 3.00	diclo		Modera te	5	3	Yes	No	No	Modera te	4	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
52	TARA	8712	25	1	9	38	5	38.7		1	0 0	0	0	co	NO	12.0	0 2.0	0 3.64	Ibuprofe	n	Modera te	4	3	Yes	No	No	Modera te	4	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
53	HASINABEGAM	9095	25	1	5	38	3	38.4		2	0 0	0	1	cc	NO	25.0	0 1.5	0 3.30	diclo		Modera te	5	3	No	No	No	Modera	4	No	No	No	Satisfactory		No	No	No	No Co	omplete	no
54	GEETHA	9104	30	1	7	38	5	38.7		2	0 0	0	1	cc	NO	11.0	0 1.0	0 2.24	buprofe	n	Severe	8	4	Yes	No	No	Modera	4	No	No	No	Superficial		No	No	yes	No in	complet	yes
55	AMRUTA	9122	25	1	5	40	0	40		1	0 0	) 0	0	co	NO	16.0	0 2.0	0 3.20	buprofe	n	Mild	2	3	No	No	No	te No	0	No	No	No	Gaping Satisfactory		No	No	No	e No Co	omplete	no
56	SUJATA	9852	26	2	0	39	5	39.7		6	1 1	1 0	2	cr	NO	9.00	1.0	0 3.00	diclo		Modera	6	3	Yes	No	No	Modera	5	No	No	No	Satisfactory		No	No	No	No Cr	omplete	no
67	BHACVACUDES	0541		-		20	2	20.2					-	-		22.00		0.00	allel -		te	-	-	Vec	N-	Ne	te	-	Mc			Catlefort		Ne	Nic	Nc	No. C		
	SHAGTASHREE	3341	20	2	1	20	2	30.5		•	0	, 0	. 0	0	ON	22.0	5 1.0	J 2.90	uiclo		wodera te	U	*	145	190	NO	MIIId	4	110	ni0	140	Saustactory		INO	110	ni0	Ca	ompiete	no
58	PARAVIN	9672	22	2	2	39	6	39.9		1	0 0	0	0	co	NO	28.0	0 1.5	0 2.61	diclo		Modera	5	4	Yes	No	No	Modera te	4	No	No	No	Satisfactory		No	No	No	No Co	omplete	no

59	VIDYA	9558	23	28	39	0	39	1	0	0	0	0	сс	NO	14.0	0 1.	50 2.	50	diclo	Severe	8 4	Y Y	es	No	No	Severe	7	Yes	Yes	No	Superficial	No	No	yes	No	incomplet	yes
60	SAVITA	9525	25	21	39	0	39	1	0	0	0	0	сс	NO	29.0	0 2.0	00 2	70	diclo	Modera	5 4	Y Y	es	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	e Complete	no
61	SHAILESHSHREE	9303	25	27	38	3	38.4	2	0	0	0	1	сс	NO	18.0	0 1.0	00 2.	.00	diclo	te Modera	6 3	N	lo	No	No	Modera	4	No	No	No	Satisfactory	No	No	No	No	Complete	no
62	SANGEEETA	9917	27	20	37	2	37.3	2	1	1	0	0	сс	NO	14.0	0 1.	50 2.	80	Ibuprofen	te Modera	4 3	Y Y	es	No	No	te Modera	5	No	Yes	No	Satisfactory	No	No	No	No	Complete	no
63	DEVAMMA	13499	22	18	36	0	36	1	0	0	0	0	сс	NO	26.0	0 2.0	00 2.	.90	Ibuprofen	te Mild	2 3	N	lo	No	No	te No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
64	BHAGYASHREE	13483	24	15	39	0	39	2	1	1	0	0	сс	NO	12.0	0 2.0	00 3	10	Ibuprofen	Modera	6 3	Y.	es	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
65	SHARENNEMA	13411	28	19	39	0	39	3	1	1	0	1	cc	NO	16.0	0 2.0	00 2	71	Ibuprofen	te Severe	7 3	Y Y	6	No	No	Modera	4	No	No	No	Superficial	No	No	ves	No	Complete	00
66	VILAVLAYMI	12222	22	22	40	6	40.9	1	0	0	0	0		NO	22.0	0 1 1	00.2	70	diclo	Savara	9.4	v	~	No	No	te	7	Vor	Vor	No	Gaping	No	No	-	No	Complete	
00		15255	52	25	40	0	40.9	1	0	0	0			NO	22.0	0 1.	00 2	70	dicio	Severe				NO	NO	Severe	′ •	res	res	NO	Gaping	NO	NO	yes	NO	Complete	no
67	SUNITA	131/1	23	24	38	3	38.4	2	0	0	0	1		NU	10.0	0 1.0	00 2.	/0	buproten	Mild	3 3		10	NO	NO	NO	0	NO	NO	NO	Satisfactory	NO	NO	NO	NO	Complete	no
68	SAVITRI	10697	21	21	42	0	42	2	1	1	0	0	сс	NO	22.0	0 2.0	00 2.	.30	diclo	Severe	8 4	Y Y	es	No	No	Modera te	5	No	Yes	No	Satisfactory	No	No	No	No	Complete	no
69	ARCHANA	10637	18	20	38	5	38.7	1	0	0	0	0	сс	NO	12.0	0 1.0	00 2.	80	Ibuprofen	Modera te	6 3	N	lo	No	No	Modera te	4	No	No	No	Satisfactory	No	No	No	No	Complete	no
70	MEGHA	106777	19	17	36	5	36.7	1	0	0	0	0	сс	NO	19.0	0 1.0	00 2.	60	Ibuprofen	Modera te	5 3	N	lo	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
71	SUCHITRA	10831	24	17	40	0	40	2	0	0	0	1	сс	NO	16.0	0 2.0	00 3.	40	Ibuprofen	Modera te	5 3	N	lo	No	No	Modera te	4	No	No	No	Satisfactory	No	No	No	No	Complete	no
72	VIDYASHREE	10866	26	15	41	0	41	2	1	1	0	0	сс	NO	15.0	0 1.0	00 3.	00	Ibuprofen	Modera te	4 3	N	lo	No	No	Modera te	4	No	No	No	Satisfactory	No	No	No	No	Complete	no
73	KAREHEENA	16350	20	16	38	4	38.6	1	0	0	0	0	сс	NO	27.0	0 2.0	00 2	50	diclo	Modera	4 3	N	lo	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
74	SHEELA	12503	30	19	37	3	37.4	1	0	0	0	0	сс	NO	20.0	0 1.0	00 2.	10	Ibuprofen	Modera	4 3	N	lo	No	No	Modera	4	No	No	No	Satisfactory	No	No	yes	No	Complete	no
75	SAVITA	13460	22	21	40	5	40.7	1	0	0	0	0	сс	NO	20.0	0 2.0	00 2	70	Ibuprofen	Modera	5 3	Y Y	es	No	No	Modera	5	No	No	No	Satisfactory	No	No	No	No	Complete	no
76	MEENAKSHI	14614	21	20	38	6	38.9	2	1	1	0	0	сс	YES	12.0	0 1.	50 2.	40	diclo	te Modera	6 4	Y Y	es	No	No	te Modera	4	No	Yes	No	Satisfactory	No	No	No	No	Complete	no
77	TRIVENI	13909	22	21	37	5	37.7	2	1	1	0	0	сс	NO	16.0	0 1.0	00 2	30	Ibuprofen	te Modera	4 4	N	lo	No	No	te Modera	4	No	No	No	Superficial	No	No	No	No	Complete	no
78	ROOPA	15036	31	22	39	1	39.1	2	0	0	0	1	сс	NO	12.0	0 2.0	00 3.	40	diclo	te Modera	4 3	N	lo	No	No	te Modera	5	No	No	No	Gaping Satisfactory	No	No	No	No	Complete	no
79	ROOPA	15567	22	17	39	4	39.6	2	1	1	0	0	сс	NO	13.0	0 2.0	00 3.	40	diclo	Mild	3 3	N	lo	No	No	ta No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
80	SIDDAMMA	14923	23	18	40	0	40	2	0	0	0	1	сс	NO	12.0	0 1.	50 2	70	diclo	Modera	5 3	Y.	es	No	No	Modera	4	No	No	No	Satisfactory	No	No	No	No	Complete	no
81	KAVITA	16579	30	19	39	1	39.1	2	1	1	0	0	сс	NO	20.0	0 1.	50 3.	.00	diclo	te Severe	7 4	Y Y	es	No	No	te Modera	4	No	Yes	No	Superficial	No	No	No	No	Complete	no
82	BHAGYASHREE	15455	25	21	40	3	40.4	2	1	1	0	0	сс	NO	21.0	0 1.0	00 2.	48	diclo	Modera	4 3	N	lo	No	No	te Modera	4	No	No	No	Gaping Satisfactory	No	No	No	No	Complete	no
83	GANGABA	14749	25	20	38	3	38.4	3	1	1	0	1	сс	NO	22.0	0 1.0	00 2	50	diclo	te Mild	2 3	N	lo	No	No	te No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
84	ASHWINI	14815	22	22	36	6	36.9	2	1	1	-	-		NO	22.0	0 1	50 2	30	diclo	Modera	4 3	I N	lo	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	
0.5	CUAL ATA	14015	22	22	30	0	30.5	-	-	-	0	0		NO	22.0	0 1.	30 2	30	human	te	•			No	No	NO	-		No	No	Satisfactory	No	No	No	No	Complete	no
85	SHAILATA	15918	26	23	39	1	39.1	1	0	0	0	U	u	NU	14.0	0 2.0	00 3.	.34	looproteit	Severe	/ 3		es	NO	NO	Severe	<u>′</u>	res	res	NO	Satisfactory	NO	NO	NO	NO	Complete	no
86	SHAGUFTABEGUM	15542	25	21	39	4	39.6	2	1	1	0	0	сс	NO	12.0	0 1.	50 2.	.90	buprofen	Mild	3 3	N	lo	No	No	No	0	No	No	No	Satisfactory	No	No	yes	No	incomplet e	yes
87	DEEPA	17884	21	20	41	0	41	1	0	0	0	0	сс	NO	17.0	0 2.0	00 3.	.00	diclo	Modera te	5 3	Y Y	es	No	No	Modera te	4	No	Yes	No	Satisfactory	No	No	No	No	Complete	no
88	KAVERI	18016	28	19	39	0	39	2	1	1	0	0	сс	NO	13.0	0 1.	50 2.	.90	diclo	Severe	8 4	Y	es	No	No	Severe	7	Yes	Yes	No	Satisfactory	No	No	No	No	Complete	no
89	HEENA	18019	28	21	38	0	38	2	1	1	0	0	сс	NO	18.0	0 2.0	00 2.	70	diclo	Severe	8 5	Y	es	No	No	Modera te	5	No	No	No	Satisfactory	No	No	No	No	Complete	no
90	SANIYA	18077	23	22	39	3	39.4	1	0	0	0	0	сс	NO	14.0	0 1.	50 2.	80	Ibuprofen	Mild	2 3	N	lo	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
91	RAJESHWARI	18066	30	19	41	5	41.7	2	1	1	0	0	сс	NO	20.0	0 1.	50 3	20	diclo	Modera	5 3	N	lo	No	No	Mild	3	No	No	No	Satisfactory	No	No	yes	No	incomplet	yes
92	POOJA	28082	26	26	38	0	38	1	0	0	0	0	сс	NO	12.0	0 1.	50 2.	80	diclo	Severe	8 4	Y Y	es	No	No	Modera	4	No	Yes	No	Satisfactory	No	No	No	No	Complete	no
93	SUNITA	18748	25	20	38	0	38	3	2	2	0	0	сс	NO	20.0	0 2.0	00 3.	10	Ibuprofen	Mild	2 3	N	lo	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
94	SHWETA	18357	25	21	38	2	38.3	1	0	0	0	0	сс	NO	12.0	0 1.0	00 2	70	diclo	Modera	6 4	N	lo	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
95	KAVERI	18593	20	22	39	3	39.4	1	0	0	0	0	сс	NO	16.0	0 2.0	00 2.	80	Ibuprofen	te Modera	5 4	N	lo	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
96	RAJMA	19019	22	18	39	0	39	2	1	1	0	0	сс	NO	15.0	0 1.0	00 2.	50	Ibuprofen	te Modera	4 3	Y Y	es	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
97	LALITA	20031	24	17	37	0	37	1	0	0	0	0	сс	NO	20.0	0 1.0	00 2.	80	Ibuprofen	te Modera	4 3	i Y	es	No	No	Mild	2	No	No	No	Satisfactory	No	No	yes	No	incomplet	yes
98	KOMAL	21638	26	16	38	0	38	1	0	0	0	0	сс	NO	19.0	0 1.	50 2.	.50	Ibuprofen	te Mild	1 3	N	lo	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	e Complete	no
99	ITOYL	21738	30	18	39	0	39	2	0	0	0	1	сс	NO	15.0	0 1.0	00 2.	50	Ibuprofen	Modera	6 4	Y Y	es	No	No	Mild	2	No	Yes	No	Satisfactory	No	No	No	No	Complete	no
100	BHAGYAMMA	26343	22	19	40	0	40	1	0	0	0	0		NO	10.0	0 1 0	00 2	80	Ibuprofen	te Modera	6 3	N	lo	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	
101	DEVANANA	42280	26	20	20	4	20.6	2	1	0	1	1	EAD	NO	20.0	0 1	00 2	00	hunrofen	te	2 3			No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	
101		42200	20	30	33		33.0	-	-	0	1	-	540	NO	20.0	0 1.	00 3.	40	huarafan	Madaa				No	No	NO NO	2		No	No	Satisfactory	No	No	No	No	Complete	no
102	ALSHAIA	43033	22	21	37	1	37.1	1	0	0	0	0	FAP	NU	18.0	J 1.0	JU 2.	48	Juli	te	• 3	N	U	NO	ON	Mild	4	190	NO.	NO	satisfactory	No	NO	NO	NO	complete	no
103	PAVITRA	43504	25	22	39	z	39.3	2	0	0	0	1	FAP	NO	15.0	U 1.	50 2.	70	diclo	Mild	z 2	N	10	No	NO	No	U	NO	No	No	satisfactory	No	No	No	No	complete	no
104	RAJESHREE	43828	30	18	38	4	38.6	2	1	1	0	0	FAP	NO	16.0	0 1.	50 2.	50	diclo	Severe	64	Y	es	No	Super ficial	Modera te	5	Yes	Yes	No	Superficial Gaping	No	No	No	No	Incomplet e	yes
105	AISHWARYA	43845	19	17	38	6	38.9	1	0	0	0	0	FAP	YES	25.0	0 1.0	00 2.	80	diclo	Mild	3 3	N	lo	No	Gapin No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
106	KOMAL	43856	27	16	40	0	40	1	0	0	0	0	FAP	NO	18.0	0 1.0	00 2.	70	diclo	Modera	6 3	N	lo	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
107	IRAMMA	43861	20	24	37	5	37.7	1	0	0	0	0	FAP	NO	16.0	0 1.	50 2	90	diclo	te Modera	4 3	N N	lo	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
108	ANITA	43955	25	27	38	0	38	5	,	1	0	3	FAP	NO	18.0	0 1 4	00 2	80	diclo	te Mild	3 3	N	lo	No	No	No	0	No	Ne	No	Satisfactory	No	No	No	No	Complete	ne
109	CHACHIKALA	2572	21	23	34	4	26.6	1	1	-	0	0	EAD	NO	18.0	0 1	50 2	50	buprofen	Moder	4			Ne	No	Mild	2	No	Ne	N-	Satisfactory	No	N-	No	No	Complet	
110	JE DEDIATI	2068	21	2.5	50		30.0	-	0	0	0	0	r AP	NC	10.0	0 1.	50 2	.50	huntofee	te		N		Ne.	red Former	Mild	-	NU Kar	nio Nic	NO.	Setisfect	110	NO	NO.	NO NO	Complete	no
110	ncVAII	2908	27	21	40	1	40.1	1	0	0	0	U	FAP	NO	15.0	0 1.	5U 2.	00	Sobioleu	modera te	4 4	Y	ద	NO	super ficial Capir	MIID	1	res	NO	NO	adistactory	NO	NO	NO	NO	complete	no
111	SNEHA	2568	22	22	40	4	40.6	1	0	0	0	0	FAP	NO	17.0	0 1.0	00 3	20	Ibuprofen	Modera	4 4	N	10	No	Gapin No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
112	AISHWARYA	3108	19	20	37	3	37.4	1	0	0	0	0	FAP	NO	20.0	0 1.0	00 2.	40	diclo	te Mild	2 2	N	lo	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
113	ASHWINI	3684	18	22	38	0	38	1	0	0	0	0	FAP	NO	16.0	0 1.0	00 2.	50	Ibuprofen	Mild	2 2	N	lo	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
114	SNEHA	3668	22	17	40	4	40.6	1	0	0	0	0	FAP	NO	18.0	0 1.0	00 3.	20	Ibuprofen	Modera	6 3	N	lo	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
115	KAVITA	3129	28	16	39	0	39	2	1	1	0	0	FAP	NO	20.0	0 1	00 3	12	Ibuprofen	te Modera	5 4	v.	es	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	ne
116	MAHANDA	3445	2.9	20	40	0	40	,	,	1	0	0	EAD	NO	14.0	0 2	00 2	20	buprofen	te	2 7	- P.	-	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	
110	MARANUA	3445	28	20	40	v	40	2	1	1	U	U.	rAP	UN	14.0	J 2.0	JU 3.	20	Jop-Oren	Dillo	1 <sup>4</sup>   <sup>2</sup>	N	N,	IND		NO	J	eD.	ni0	ni0	odusidetory	NO	niO	n O	NO	complete	nò

117	ANJANA	3394	25	21	39	2	39.3	1	0	0	0	0	FAP NO	19.00	1.00	3.10	Ibuprofen	Modera 5	4	NO	No	No	No	0	No	Yes	No	Superficial	No	No	No	No	Incomplet	yes
118	LAMMBAI	3949	21	22	38	3	38.4	3	1	1	0	1	FAP NO	16.00	1.50	3.20	Ibuprofen	Modera 5	4	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	e Complete	no
119	KAVERI	4094	24	23	40	3	40.4	2	1	1	0	0	FAP NO	18.00	1.00	2.62	diclo	Mild 3	4	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
120	AMMITA	3966	21	21	38	6	38.9	1	0	0	0	0	FAP NO	15.00	1.50	2.82	Ibuprofen	Modera 6	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
121	BHAGYASHREE	3856	20	21	36	3	36.4	2	0	0	0	1	FAP NO	18.00	1.00	2.30	Ibuprofen	te mild 3	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
122	KALIBAI	4014	23	20	38	1	38.1	1	0	0	0	0	FAP NO	10.00	1.50	2.70	Ibuprofen	Mild 3	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
123	SAUBAGYA	4513	23	26	38	5	38.7	1	0	0	0	0	FAP NO	15.00	1.00	3.30	Ibuprofen	Modera 6	3	No	No	No	Mild	2	No	Yes	No	Satisfactory	No	No	No	No	Complete	no
124	NAGAMMA	4614	24	24	40	4	40.6	1	0	0	0	0	FAP NO	16.00	1.50	2.89	Ibuprofen	te Modera 4	3	Yes	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	00
125	454ITA	9126	22	22	20	0	20	2	1	1	0	0		14.00	1.50	2 64	Ibuprofen	te Modera 4	2	No	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	
125	TAGI FENI	8007	2.5	17	40	2	40.2	-			0	0		17.00	1.50		diala	te	2	No	No	Ne	halled	3	No	No	No	Catlefactory	No	No		No	Complete	110
120	IASLEEN	6997	24	1/	40	2	40.5	2	1	1	0		FAP NO	17.00	1.50	5.00	dicio	te	3	NO	NO	NO	Mild	1	NO	NO	NO	Satisfactory	NO	NO	NO	NO	complete	no
127	VIDYASHREE	9534	24	18	37	5	37.7	2	0	0	0	1	FAP NO	16.00	1.00	2.40	diclo	Mild 3	2	No	NO	NO	NO	0	No	No	NO	Satisfactory	NO	NO	No	NO	Complete	no
128	VIDYASHREE	10866	26	19	41	0	41	2	0	0	0	1	FAP NO	15.00	1.00	3.00	diclo	Mild 3	3	No	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
129	LAXMI	11092	24	17	38	4	38.6	3	1	1	0	1	FAP NO	10.00	1.00	2.60	Ibuprofen	Mild 1	2	Yes	No	No	Mild	3	Yes	No	No	Superficial Gaping	No	No	No	No	Incomplet e	yes
130	ARCHANA	10637	18	21	36	5	36.7	1	0	0	0	0	FAP NO	13.00	1.50	2.60	Ibuprofen	Modera 2 te	3	No	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
131	SUVARNA	13494	23	20	38	5	38.7	3	1	1	0	1	FAP NO	13.00	1.00	3.20	diclo	Mild 6	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
132	VIDYA	13416	24	22	38	3	38.4	2	1	1	0	1	FAP NO	12.00	1.00	2.80	Ibuprofen	Modera 4 te	3	No	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
133	VIJAYALAKSHMI	13414	22	18	39	0	39	1	0	0	0	0	FAP YES	12.00	1.00	2.90	Ibuprofen	Modera 5	3	No	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
134	RAJASREE	13406	34	19	36	6	36.9	2	1	1	0	0	FAP NO	13.00	1.00	3.50	Ibuprofen	Mild 3	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
135	SHANYA	13498	25	14	38	0	38	3	1	0	1	2	FAP NO	12.00	1.00	2.70	Ibuprofen	Modera 5	3	Yes	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
136	AMBAVVA	13350	28	17	38	3	38.4	2	0	0	0	1	FAP NO	13.00	1.50	2.80	diclo	Modera 5 te	3	Yes	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
137	CHINNAKKA	13343	24	19	38	2	38.3	2	1	1	0	0	FAP NO	12.00	1.00	2.80	Ibuprofen	Mild 3	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
138	BHARATI	13312	24	15	36	0	36	3	1	1	0	1	FAP NO	13.00	1.00	3.30	Ibuprofen	Modera 4	3	No	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
139	AKSHATA	13230	21	14	39	0	39	1	0	0	0	0	FAP NO	12.00	1.50	3.20	diclo	Modera 5	4	No	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
140	KAVERI	13175	24	21	37	0	37	2	1	0	1	0	FAP NO	10.00	1.00	2.60	diclo	Mild 2	2	Yes	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
141	MEENAKSHI	13060	23	20	39	0	39	1	0	0	0	0	FAP NO	13.00	1.00	2.50	Ibuprofen	Modera 5	3	No	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
142	DEVAMMA	13499	22	22	38	0	38	1	0	0	0	0	FAP NO	12.00	1.00	3.00	Ibuprofen	te Mild 2	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
143	MEENAKSHI	13060	23	26	39	0	39	1	0	0	0	0	FAP NO	13.00	1.00	3.50	Ibuprofen	Mild 3	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
144	REKHA	13016	21	21	40	4	40.6	1	0	0	0	0	FAP NO	9.00	1.00	3.10	Ibuprofen	Modera 5	4	No	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
145	SAKKUBAI	13012	20	18	41	4	41.6	1	0	0	0	0	FAP NO	16.00	1.00	3.04	Ibuprofen	te Mild 3	3	Yes	No	Super	Modera	4	Yes	Yes	No	Satisfactory	No	No	No	No	Complete	no
																						ficial Gapin	te											
146	KAVERI	12961	29	16	38	3	38.4	2	1	1	0	0	FAP NO	12.00	1.50	2.45	Ibuprofen	Modera 5 te	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
147	SUREKHA	12955	21	14	39	6	39.9	1	0	0	0	0	FAP NO	15.00	1.50	3.30	Ibuprofen	Modera 5	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
148	NARMADA	12901	28	19	40	3	40.4	2	1	1	0	0	FAP NO	8.00	1.00	2.50	Ibuprofen	Modera 5	3	No	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
149	SUNITADEVI	12890	18	30	36	3	36.4	1	0	0	0	0	FAP NO	20.00	1.00	2.90	Ibuprofen	Mild 2	4	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
150	PARVATI	12882	21	21	38	6	38.9	2	1	1	0	0	FAP NO	12.00	1.50	2.70	Ibuprofen	Modera 6	3	Yes	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
151	RUBINA	12898	28	21	38	3	38.4	3	2	2	0	0	FAP NO	16.00	1.00	2.91	Ibuprofen	te Modera 6	3	No	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
152	LAXMI	12832	23	22	40	0	40	1	0	0	0	0	FAP NO	12.00	1.00	3.40	Ibuprofen	te Modera 4	4	Yes	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
153	KAVERI	12839	19	26	37	0	37	1	0	0	0	0	FAP NO	13.00	1.50	2.90	Ibuprofen	te Mild 2	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
154	LAXMI PUJERI	12822	22	17	36	4	36.6	2	1	0	1	0	FAP NO	12.00	1.00	2.25	Ibuprofen	Modera 6 te	3	No	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
155	SARASWATI	12790	20	18	38	4	38.6	1	0	0	0	0	FAP NO	10.00	1.00	2.50	Ibuprofen	Mild 3	4	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
156	MAHANANDA MATH	12744	21	18	40	3	40.4	2	1	1	0	0	FAP NO	11.00	1.00	3.68	Ibuprofen	Severe 9	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
157	SWATI	12747	27	15	38	4	38.6	2	1	1	0	0	FAP NO	12.00	1.00	2.20	Ibuprofen	Mild 2	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
158	AISHWARYA	12708	24	17	39	3	39.4	2	1	1	0	0	FAP NO	16.00	1.50	3.40	Ibuprofen	Modera 4	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
159	JAYASHREE	12637	22	18	40	0	40	2	1	1	0	0	FAP NO	14.00	1.00	2.70	Ibuprofen	Modera 5	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
160	POOJA	12611	20	19	40	0	40	2	1	1	0	0	FAP NO	12.00	1.50	3.19	Ibuprofen	Modera 5	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
161	ISANAT	12540	29	21	39	3	39.4	2	1	1	0	0	FAP NO	17.00	1.00	2.90	Ibuprofen	te Mild 3	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
162	ANITA	12930	26	20	39	0	39	2	1	1	0	0	FAP NO	13.00	1.00	2.26	diclo	Modera 5	3	No	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
	SAVITRI	12507	24	21	40	0	40	1	0	0	0	0	FAP NO	18.00	1.50	2.42	Ibuprofen	te Modera 5	3	No	No	No	Mild	3	No	No	No	Superficial Gaping	No	No	No	No	Incomplet	yes
163				22	39	3	39.4	2	1	1	0	0	FAP NO	16.00	1.50	2.75	diclo	te Mild 2	2	No	NO	NO	Mild	2	NO	NO	No	Satisfactory	No	No	No	No	e Complete	no
163	BHOOMIKA	12463	24		112	Ľ	1 · · · · ·	Ľ	Ē	Ĩ		0		12.00	1.00	3.00	diclo	Mild 2	2	No	No	No	No	0	Ne	No	No	Caticfactory	No	No	Ĩ			
163 164 165	BHOOMIKA	12463	24	20	38	3	38.4	1	0	0	0		1.000				and the second sec	1	11				1.1.1	17 I I		1 M		Satistactory		140	NO	NO	Complete	
163 164 165	BHOOMIKA MALLAMA	12463 12424	24	20	38	3	38.4	1	0	0	0	0		20.00	1.00	2 10	buorofeo	Modern	2	Nc	N-	No	No	0	Nc	Ne	N-	Satisfactory	Ala	No.	NO No	No	Complete	10
163 164 165 166	BHOOMIKA MALLAMA BHAGYAVATHI	12463 12424 12375	24 20 20	20	38 38	3	38.4 38.7	1	0	0	0	0	FAP NO	20.00	1.00	2.10	Ibuprofen	Modera 4 te	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
163 164 165 166 167 168	BHOOMIKA MALLAMA BHAGYAVATHI MAMATA SUNITA	12463 12424 12375 12394 13171	24 20 20 22 23	20 21 22 18	38 38 40 38	3 5 0 3	38.4 38.7 40 38.4	1 1 1 2	0 0 0 0	0 0 0 0 0	0 0 0	0	FAP NO Faa NO FAP NO	20.00 12.00 16.00	1.00 1.00 1.50	2.10 2.60 2.70	Ibuprofen diclo Ibuprofen	Modera 4 te Mild 1 Modera 4	3 2 3	No No No	No No No	No No No	No No No	0	No No No	No No No	No No No	Satisfactory Satisfactory Satisfactory	No No No	No No No	No No No	No No No	Complete Complete Complete COMplete	no no no
163 164 165 166 167 168 169	BHOOMIKA MALLAMA BHAGYAVATHI MAMATA SUNITA MAHANDA VINOD	12463 12424 12375 12394 13171 12779	24 20 20 22 23 21	20 21 22 18 22	38 38 40 38 40	3 5 0 3 2	38.4 38.7 40 38.4 40.3	1 1 2 2	0 0 0 0	0 0 0 0	0 0 0 0 0 0	0 0 1 0	FAP NO FAA NO FAP NO FAP NO	20.00 12.00 16.00 10.00	1.00 1.00 1.50	2.10 2.60 2.70 2.67	lbuprofen diclo lbuprofen diclo	Modera 4 te 4 Mild 1 Modera 4 te 2	3 2 3 2	No No No No	No No No	No No No No	No No No No	0 0 0	No No No	No No No	No No No	Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory	No No No No	No No No No	No No No No	No No No No	Complete Complete Complete COMplete Complete	no no no no
163 164 165 166 167 168 169 170	BHOOMIKA MALLAMA BHAGYAVATHI MAMATA SUNITA MAHANDA VINOD RAJASHREE	12463 12424 12375 12394 13171 12779 13406	24 20 20 22 23 21 34	20 21 22 18 22 17	38 38 40 38 40 36	3 5 0 3 2 6	38.4 38.7 40 38.4 40.3 36.9	1 1 2 2	0 0 0 1	0 0 0 1	0 0 0 0	0 0 1 0	FAP NO FAP NO FAP NO FAP NO FAP NO	20.00 12.00 16.00 10.00 13.00	1.00 1.00 1.50 1.00	2.10 2.60 2.70 2.67 2.90	lbuprofen diclo lbuprofen diclo lbuprofen	Modera 4 te 4 Mild 1 Modera 4 te 2 Mild 2 Mild 2	3 2 3 2 2 2	No No No No	No No No No	No No No No	No No No No	0 0 0 0	No No No No	No No No No	No No No No	Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory	No No No No	No No No No	No No No No No	No No No No	Complete Complete COMplete COMplete Complete Complete	no no no no
163 164 165 166 167 168 169 170 171	BHOOMIKA MALLAMA BHAGYAVATHI MAMATA SUNITA MAHANDA VINOD RAJASHREE SHARANAMMA	12463 12424 12375 12394 13171 12779 13406 13411	24 20 22 23 21 34 28	20 21 22 18 22 17 26	38 38 40 38 40 36 38	3 5 0 3 2 6 0	38.4 38.7 40 38.4 40.3 36.9 38	1 1 2 2 1	0 0 0 1 0	0 0 0 1 0	0 0 0 0 0	0 0 1 0 0	FAP         NO	20.00 12.00 16.00 10.00 13.00 12.00	1.00 1.00 1.50 1.00	2.10 2.60 2.70 2.67 2.90 2.70	Ibuprofen diclo Ibuprofen diclo Ibuprofen Ibuprofen	Modera 4 te Mild 1 Modera 4 te Mild 2 Mild 2 Mild 2 Modera 4	3 2 3 2 2 2 3	No No No No No No	No No No No No	No No No No No No	No No No No No	0 0 0 0	No No No No	No No No No No	No No No No No	Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory	No No No No No	No No No No No	No No No No No	No No No No No	Complete Complete COMplete COMplete Complete Complete Complete	no no no no no
163 164 165 166 167 168 169 170 171	BHOOMIKA MALLAMA BHAGYAVATHI MAMATA SUNITA MAHANDA VINOD RAJASHREE SHARANAMMA VIDYA	12463 12424 12375 12394 13171 12779 13406 13411 13416	24 20 22 23 21 34 28 21	20 21 22 18 22 17 26 24	38 38 40 38 40 36 38 38	3 5 0 3 2 6 0	38.4 38.7 40 38.4 40.3 36.9 38 38.4	1 1 2 1 1 1 2	0 0 0 1 0 0	0 0 0 0 1 0 0 0		0 0 1 0 0 0	FAP         NO           FAP         NO	20.00 12.00 16.00 10.00 13.00 12.00	1.00 1.00 1.50 1.00 1.00	2.10 2.60 2.70 2.67 2.90 2.70 2.70	Buprofen diclo diclo diclo diclo diclo diclo diclo diclo dibuprofen dibuprofe	Modera 4 te 1 Mild 1 Modera 4 te 2 Mild 2 Modera 4 te 1 Mild 2	3 2 3 2 2 2 3 3	No No No No No No	No No No No No	No No No No No No	No No No No No No	0 0 0 0 0	No No No No NO	No No No No No Yes	No No No No No	Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory Satisfactory	No No No No No	No No No No No	No No No No No	No No No No No No	Complete Complete COMplete COMplete Complete Complete Complete	

173	VIJAYALAKSHMI	13414	22	17	39	6	39.9	2	0	0	0	1	FAP	NO	12.00	1.50	2.70	lbuprofen	Modera te	6	3	Yes	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
174	VIDYA KABER	13416	24	15	38	3	38.4	2	0	0	0	1	FAP	NO	12.50	1.00	2.30	Ibuprofen	Modera te	5	3	Yes	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	COmplete	no
175	BHAGYASHREE	13483	24	18	39	0	39	1	0	0	0	0	FAP	NO	13.00	1.00	3.10	diclo	Mild	3	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
176	KAMALABAI	13496	30	19	36	0	36	1	0	0	0	0	FAP	NO	10.00	1.00	2.90	Ibuprofen	Modera te	4	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
177	SAVITRI	10697	21	19	42	0	42	2	1	1	0	0	FAP	NO	13.00	1.00	2.30	diclo	Mild	2	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
178	ARCHANA	10637	18	22	38	5	38.7	1	0	0	0	0	FAP	NO	12.00	1.50	2.80	Ibuprofen	Mild	2	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
179	MEGHA	10677	19	20	36	5	36.7	1	0	0	0	0	FAP	NO	13.00	1.00	2.60	lbuprofen	Severe	8	4	Yes	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
180	SUCHITRA	10831	24	18	40	0	40	1	0	0	0	0	FAP	NO	12.00	1.00	3.40	Ibuprofen	Mild	3	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
181	REKHA	13842	23	16	40	0	40	2	1	1	0	0	FAP	NO	12.00	1.00	2.76	Ibuprofen	Modera te	5	3	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
182	SUVARNA	13457	23	17	38	5	38.7	3	1	1	0	1	FAP	NO	13.00	1.50	2.35	diclo	Mild	2	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
183	BHAGYASHREE	13483	24	18	39	0	39	2	1	1	0	0	FAP	NO	12.00	1.00	3.10	Ibuprofen	Modera te	5	4	No	No	No	Mild	3	No	No	No	Satisfactory	No	No	No	No	Complete	no
184	VIDYA	13416	24	30	38	3	38.4	2	0	0	0	1	FAP	NO	13.00	1.50	2.30	Ibuprofen	Mild	2	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
185	VIJAYALAKSHMI	13414	22	26	39	0	39	1	0	0	0	0	FAP	NO	12.00	2.00	2.80	Ibuprofen	Severe	8	5	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
186	RAJASREE	13406	34	24	36	6	36.9	2	1	1	0	0	FAP	NO	13.00	1.00	2.90	Ibuprofen	Mild	2	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
187	SHARANAMMA	13411	28	22	39	0	39	3	1	1	0	1	FAP	YES	12.00	2.00	2.70	Ibuprofen	Mild	2	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
188	SHANAYA	13498	25	22	38	0	38	3	0	0	0	2	FAP	NO	13.00	1.50	3.00	Ibuprofen	Modera te	4	4	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
189	AMBAVVA	13350	28	21	38	3	38.4	2	1	1	0	0	FAP	NO	12.00	1.00	3.39	diclo	Modera te	4	4	No	No	No	Mild	2	No	Yes	No	Satisfactory	No	No	No	No	Complete	no
190	CHINNAKKA	13343	24	18	38	2	38.3	2	1	1	0	0	FAP	NO	13.00	1.50	2.60	Ibuprofen	Mild	2	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
191	BHARATI	13312	24	19	36	0	36	3	1	1	0	1	FAP	YES	12.00	2.00	2.60	Ibuprofen	Modera	4	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
192	AKSHATA	13230	21	16	39	0	39	1	0	0	0	0	FAP	NO	13.00	1.00	3.10	Ibuprofen	Mild	3	4	No	No	No	Mild	3	No	Yes	No	Satisfactory	No	No	No	No	Complete	no
193	KAVERY	13175	24	19	37	0	37	2	1	0	1	0	FAP	NO	12.00	1.50	2.58	diclo	Mild	3	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	incomplet e	: yes
194	REKHA	13016	21	14	40	4	40.6	1	0	0	0	0	FAP	NO	18.00	2.00	3.00	Ibuprofen	Severe	8	4	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
195	SAKKUBAI	13012	20	16	41	4	41.6	1	0	0	0	0	FAP	NO	12.00	1.50	3.30	Ibuprofen	Mild	3	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
196	KAVERI	12961	25	21	38	3	38.4	2	1	1	0	0	FAP	NO	13.00	2.00	2.45	Ibuprofen	Mild	3	2	Yes	No	No	Mild	2	No	No	No	Satisfactory	No	No	No	No	Complete	no
197	SUREKHA	12955	21	22	39	6	39.9	1	0	0	0	0	FAP	NO	12.00	1.50	3.30	Ibuprofen	Modera te	6	2	No	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
198	NARMADA	12901	28	32	40	3	40.4	2	1	1	0	0	FAP	NO	15.00	1.00	2.80	Ibuprofen	Mild	3	3	Yes	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
199	SUNITADEVI	12890	18	21	36	3	36.4	1	0	0	0	0	FAP	NO	12.00	1.00	2.90	Ibuprofen	Severe	7	4	Yes	No	No	No	0	No	No	No	Satisfactory	No	No	No	No	Complete	no
200	PARVATI	12882	21	15	38	6	38.9	2	1	1	0	0	FAP	NO	13.00	1.00	2.70	Ibuprofen	Modera te	6	4	No	No	No	Mild	2	No	Yes	No	Satisfactory	No	No	No	No	Complete	no